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MOLECULAR MECHANISMS OF  
THROMBOXANE A2 RECEPTOR-MEDIATED INVASION  
IN LUNG CANCER CELLS 
 
        Thromboxane A2 receptor (TP) has been shown to play important roles in multiple 
aspects of cancer development including regulation of tumor growth, survival and 
metastasis. Molecular mechanisms of TP mediated cancer cell invasion remain to be 
identified. TP agonist, I-BOP, significantly elevated several matrix metalloproteinases 
(MMPs) including MMP-1, MMP-3, MMP-9 and MMP-10 in A549 human lung 
adenocarcinoma cells overexpressing TPα (A549-TPα) or TPβ (A549-TPβ).  Signaling 
pathways of I-BOP-induced MMP-1 expression were examined in further detail as a 
model system for MMPs induction.  Signaling molecules involved in I-BOP-induced 
MMP-1 expression were identified by using specific inhibitors including small interfering 
(si)-RNAs of signaling molecules and promoter reporter assay. The results indicate that I-
BOP-induced MMP-1 expression is mediated by protein kinase C (PKC), extracellular 
signal-regulated kinase (ERK)-activator protein-1(AP-1) and ERK-CCAAT/enhancer-
binding protein β (C/EBPβ) pathways.  I-BOP-induced cellular invasiveness of A549-
TPα cells was blocked by, GM6001, a general inhibitor of MMPs.  Knockdown of MMP-
1 and MMP-9 by their respective siRNA partially reduced I-BOP-stimulated A549-TPα 
cells invasion suggesting that other MMPs induced by I-BOP were also involved.   
        Furthermore, secreted MMP-1 in conditioned media from I-BOP-treated A549-TPα 
cells (CM-I-BOP) autocrinely induced monocyte chemoattractant protein-1 (MCP-1) 
expression. The induction of MCP-1 by MMP-1 in A549 cells was via activation of 
protease-activated receptor 2 (PAR2) instead of commonly assumed PAR1. This 
conclusion was reached from the following findings: (1) expression of MCP-1 induced by 
trypsin, a PAR2 agonist, was inhibited by a PAR2 antagonist.  (2) expression of MCP-1 
induced by MMP-1 and by CM-I-BOP was blocked by a PAR2 antagonist but not by 
other PAR antagonists; (3) expression of MCP-1 induced by MMP-1 and by CM-I-BOP 
was attenuated significantly by pretreatment of cells with PAR2-siRNA. 
        Finally, MCP-1 also can be induced by direct activation of TP in a SP1 involved 
mechanism. CM-I-BOP enhanced MCP-1-dependent migration of RAW 264.7 
 
 
macrophages.  Co-culture of A549 cells with RAW 264.7 macrophages induced 
expression of MMPs, VEGF and MCP-1 genes, and increased the invasive potential in 
A549 cells. 
        My studies provide molecular mechanisms by which TP-mediated cancer cell 
invasion and suggest that TP is a potential anti-cancer drug target.  
Key words: Thromboxane A2 Receptor, Invasion, Matrix Metalloproteinases,      
                    Monocyte Chemoattractant Protein-1, Protease-Activated Receptor 
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1.1 Thromboxane A2 (TXA2) and its biological function 
1.1.1 Discovery of TXA2 and its biosynthesis 
        Thromboxane A2 (TXA2) was originally discovered by Piper and Vane as a rabbit 
aorta contracting substance (RCS) in 1969 [1]. The release of RCS was reduced by 
steroidal and non-steroidal anti-inflammatory drugs suggesting the association of RCS 
with prostaglandins [2]. In 1975, Hamberg et al. reported that RCS actually was TXA2 
derived from arachidonic acid (AA) and prostaglandin G2 (PGG2) [3]. Because TXA2 has 
a very short half-life of only 34 seconds in aqueous solution, they proposed a chemical 
structure of TXA2 from indirect experiments by trapping it with nucleophiles such as 
CH3O-. This structure was finally confirmed by Bhagwat et al. in 1985 [4]. 
        TXA2 is one of the five primary prostanoids generated from AA through 
cyclooxygenase (COX) pathway. The biosynthesis of TXA2 and other prostaglandins 
involves three sequential steps (Figure 1): 
(1) Release of AA from cell membrane phospholipids by phospholipase A2 (PLA2). 
(2) Conversion of AA to prostaglandin H2 (PGH2) by COX-1 and COX-2.  
(3) Isomerization of PGH2 to TXA2 and other PGs by their specific synthases or 
isomerases.  
The second step is believed to be the rate-limiting step for generation of TXA2 and other 
PGs. Two isoforms of COX have been described. COX-1 is constitutively expressed and 
is involved in normal physiological functions, such as platelet aggregation, gastric 
mucosa protection and renal functions, whereas, COX-2 is an inducible isoform 
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associated with pathological functions such as inflammation, cardiovascular disease and 
cancer.  
        The enzyme converted PGH2 to TXA2 is thromboxane A2 synthase (TXAS), which 
was first found in platelet microsomes [5], then was reported to express in many other 
tissues such as lung, platelets, kidney, stomach, duodenum, colon and spleen [6, 7].   
        As mentioned above, TXA2 is very unstable and rapidly, non-enzymatically 












Figure 1. Schematic presentation of thromboxane A2 synthesis 
PLA2 catalyzes phospholipids to form arachidonic acid (AA). Then AA is metabolized by 
COX-1 and COX-2 to form prostaglandin H2 (PGH2), which is converted into PGs by 
specific synthases.   
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1.1.2 Physiology and pathophysiology of TXA2  
 
        TXA2 has a broad range of bioactivities. It induces vascular smooth muscles 
contraction, revealing its contribution to hypertension. It also causes contraction of 
bronchial smooth muscles, which may result in asthma. TXA2 is a potent platelet 
activator, leading to platelet shape change, secretion and aggregation, thus promoting 
thrombus formation and thrombosis. In addition, it has been shown that TXA2 stimulates 
the proliferation of several types of cells including oligodendrocytes [8], smooth muscle 
cells [9] and lung cancer cells [10]. Moreover, TXA2 is implicated to be involved in 
allergies, inflammation, acquired immunity modulation, atherogenesis, angiogenesis, and 
metastasis of cancer [11].  
1.2 Thromboxane A2 receptor (TP) and its signal transduction 
 
        TXA2 exerts its biological activities through its cell surface receptor, the T-
prostanoid (TP) receptor. TP is widely distributed in many tissues and organs, including 
brain, eye, thymus, heart, lung, aorta, liver, uterus, intestine, kidney, placenta, and 
platelets [11]. TP belongs to G-protein-coupled-receptor (GPCR) superfamily and is 
expressed as two isoforms in human, named TPα and TPβ. These TP isoforms arise from 
a single gene via alternative splicing of mRNA and share the first 328 amino acids, but 
differ in their C-terminal tails with TPβ longer than TPα (Figure 2) [12]. The ligand 
binding domain of TP resides mainly in the extracellular region of the protein, therefore 
no differences were observed in the ligand binding between TPα and TPβ, whereas there 
are some variances in the G-protein coupling of these two isoforms. TPα is coupled to Gs 
and TPβ is coupled to Gi. 
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 Figure 2. Structures of thromboxane A2 receptor α and β proteins 
 




         Due to the very unstable property of TXA2, its mimetics instead of TXA2 itself are 
used by researchers to study TP-mediated events.  U46619 and I-BOP are two synthetic 
TP specific agonists and SQ29584 is a specific TP antagonist.   








Figure 3. Structures of thromboxane A2 receptor agonists and antagonist 
 
 
        TP-mediated signal transduction is mostly achieved through activation of its coupled 
G proteins. Gq was the first found trimeric G protein coupled to TP to activate 
phospholiase C-β (PLC-β) [13], resulting in the accumulation of inositol triphosphate 
(IP3)/diacylglycerol (DAG), subsequent mobilization of intracellular calcium and 
activation of PKC. In addition to Gq, TP has been shown to be coupled with other G 
proteins, including G12 family G proteins (G12 and G13) [14], Gi [15], Gs [16] and Gh 
[17], thus activating multiple signaling pathways. G12 and G13 have been shown to 
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activate RhoGEF, following the activation of Rho-mediated signaling [18]. TP-mediated 
contraction of rat caudal arterial smooth muscle and migration of prostate cancer cells 
were reported to depend on RhoA/ROCK pathway [19, 20]. Both Gi and Gs regulate 
cyclic AMP (cAMP) levels but in opposite directions. Gi inhibits adenylyl cyclase (AC), 
thus decreasing cAMP levels, and Gs stimulates AC, thus increasing cAMP levels. The 
activity of protein kinase A (PKA) is regulated by the levels of cAMP. It has been shown 
that TPα couples to Gs, TPβ couples to Gi, and elevation of cAMP were observed in 
HEK or CHO cells expressing TPα but not TPβ [21, 22]. Therefore, TPα and TPβ may 
have distinct signal pathways to regulate cellular events. Using CHO cells stably 
expressing  TPα or TPβ, Miyosawa et al. found that TPα not TPβ-mediated activation of 
the extracellular signal regulated kinase1/2 (ERK1/2) was dependent on PKA activation 
[23]. This contradicted with an earlier report that PKA was involved in ERK activation in 
both HEK cells stably expressing TPα or TPβ [24]. This might be explained by the 
assumption that the levels of signaling molecules downstream of TP vary in different cell 
types [23].  Moreover, many studies indicated that TP-mediated signaling evens differ in 
different cell types and tissues [25]. Gh, which is a dimeric G protein, activates 
phospholipase C-δ (PLC-δ), subsequent production of IP3 and DAG, a similar response 
to that mediated by Gq. Although Gh couples to both TPα and TPβ, only TPα-Gh 
association results in a PLC-dependent IP3 signaling [17]. Dissociated from Gα subunit, 
the activated Gβγ can also mediate signaling transduction through activation of class IB 
phosphatidylinositol 3-kinase (PI3K) and ERK1/2. Although there is evidence that PI3K 
inhibitor blocked TP-mediated activation of ERK, Gβγ subunits did not seem to be 
involved in this regulation, suggesting the existence of other mechanisms than activating 
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G proteins for TP-mediated signal transduction. Further studies showed that TPα and TPβ 
directly interact with PI3K class 1A p85 adaptor subunit to regulate ERK1/2 activation 
[24]. Furthermore, activation of TP may transactivate epidermal growth factor receptor 
(EGFR) through a src-dependent mechanism, leading to the activation of ERK1/2 [24, 
26]. Moreover, it was reported that 14-3-3ζ as a scaffold protein to associate with TP and 
raf-1, therefore, mediates TP signal-regulated ERK1/2 activation [27]. G protein coupling 













Figure 4. G protein coupling of thromboxane A2 receptor and signal transduction 
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1.3 TXA2 signaling in cancer progression 
        Early in 1981, TXA2 has already been reported to stimulate melanoma tumor cells 
proliferation, suggesting its potential role in tumor progression [28]. Then, over the past 
three decades, more and more evidence indicated the important role of TXA2 signaling in 
malignancy.    
1.3.1 Thromboxane A2 synthase (TXAS), TP and cancer prognosis 
        TXAS and TP are two main components of TXA2 pathway, and both were observed 
to increase in tumor tissues from 46 patients with prostate cancer [29].  The levels of 
TXAS and TP were significantly associated with higher Gleason scores and pathologic 
stages of the tumors [29].  A large study employing 120 human breast tumor tissues 
found that TP was highly expressed in aggressive tumors (grade 3 and above) and linked 
with higher mortality and worse prognosis [30].  In addition, TXAS and TP were 
expressed at significantly higher levels in human colorectal carcinoma compared with 
normal tissues [31, 32].  Furthermore, Watson and his colleagues reported that the 
expression of TXAS was significantly elevated in invasive bladder cancer, and negatively 
correlated with patient survival. TP protein not mRNA expression was also increased in 
invasive bladder cancer tissues compared to paired normal tissues [33].  One following 
study from the same group further identified that it was the TPβ isoform highly expressed 
in bladder cancer tissues and correlated well with poor prognosis for patients [34].  
Moreover, high levels of TXB2, the stable nonenzymatic hydrolysis product of TXA2, 
were detected  in lung cancer tissues compared to normal lung tissues, suggesting the 
increased TXAS activity in lung cancer [35].  More recently, Cathart et al. examined the 
expression profile of TXAS in non-small cell lung cancer (NSCLC) in 204 patients, and 
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confirmed that TXAS and TXB2 were significantly higher in tumor tissues than the 
matched normal tissues [36].  Although TXAS was not a prognostic factor, this study 
indicated that TXAS could promote tumor progression and serve as a potential 
therapeutic target for treatment of NSCLC [36].  
 1.3.2 Mechanisms of TXA2 signaling in carcinogenesis  
         To understand the mechanisms underlying the effects of TXA2 signaling on cancer 
progression, both in vitro and in vivo studies were conducted by many researchers to 
investigate the role of TXA2 pathway in cancer biology. The results showed that TXA2 
signaling can modulate cancer progression in many aspects including tumor cells 
proliferation, apoptosis, migration, invasion, angiogenesis and the metastatic process.  
1.3.2.1 Cell survive, proliferation and apoptosis 
        TXA2 has been found to contribute to survival, proliferation and growth of several 
types of cancer cells including lung cancer, colorectal cancer, brain cancer and bladder 
cancer cells. It was reported that in nude mice tumor xenograft model, tumors from A549 
cells with ectopic TPα expression exhibited faster growth rate than those tumors from the 
control A549 cells [37]. Using another lung cancer cell line H157 which expressed 
endogenous TP, we identified that Nurr1 is a target gene of TXA2 signaling. The 
expression of Nurr1 is critical for TP-mediated H157 cell proliferation [10].   Huang et 
al. recently reported that carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone 
(NNK) increased the production of TXAS and TXA2 in vivo and in lung cancer cells in 
vitro. The increased TXA2 may subsequently activate CREB via PI3K/Akt and ERK 
pathways, thereby contributing to the NNK-induced survival and growth of lung cancer 
cells [38]. TXAS was found highly expressed in human colonic cancer cell lines. 
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Proliferation of these cells was inhibited by antisense oligonucleotide for TXAS as well 
as TP antagonists, indicating a critic role of TXA2 in colon cancer growth [31]. 
Furegrelate, a specific TXAS inhibitor, significantly inhibited glioblastoma growth 
through inducing proapoptotic, antiproliferative, and anti-angiogenic effects. Further, the 
inhibition of TXAS also increased the sensitivity to conventional alkylation 
chemotherapy in vivo [39]. Moreover, TXAS inhibitors and TP antagonists-induced 
apoptosis and increased sensitivity to chemotherapeutic agents were also found in bladder 
cancers [34, 40].   
1.3.2.2 Cell migration, invasion and metastasis  
        The most important difference between benign and malignant tumors is that the 
malignant tumors spread to other parts of the body through the lymphatic system or 
bloodstream (a process called metastasis), while benign tumors do not. Tumor cells 
migration and invasion are initial steps in metastasis. Within prostate cancer tissues, 
TXAS and TP were found highly expressed in the areas of perineural invasion which is a 
major mechanism by which tumor spread outside the prostate, indicating the involvement 
of TXA2 signaling in metastasis of prostate cancer [29, 41]. Further studies showed that 
TXAS and TXA2 signaling mediated migration and invasion in prostate cancer cells [20, 
41]. The mechanism by which TXA2 drives these processes is related to Rho signaling. 
TP is known to couple to G12 family of heterotrimeric G proteins (Gα12 and Gα13).  Kelly 
et al. reported that expression of activated G12 and G13 promoted prostate cancer cells 
invasion through activation of the RhoA family of G proteins [42].  They further 
observed that inhibition of G12 signaling blocked TXA2-induced invasion of prostate 
cancer cells suggesting the G12-RhoA signaling is involved in TP-mediated cell invasion 
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[42].  Later, Nie and colleagues demonstrated that activation of TP regulated prostate 
cancer cell motility and cytoskeleton reorganization through inducing cell contraction via 
activation of RhoA [20].  A recent study revealed that in prostate cancer cells PC3 and 
LNCaP, both TPα and TPβ constitutively interact with protein kinase C-related kinases 
(PRK1), which is a RhoA effector.  Activation of TPs enhanced PRK1 activation and 
disruption of PRK1 impaired TP-mediated cell migration [43]. In addition to prostate 
cancer, expression levels of TXAS were highly elevated in selected migration-
advantaged glioma cells. TXAS inhibitors, dazmegrel and furegrelate, reduced the 
migration rate of these cells to the rate of the parental cells, suggesting TXAS may 
influence the motility of glioma cells [44].  Further, TXB2 was detected in a wide range 
of glioma cell lines and the relative expression of which correlated with migration of 
these cell lines. Treatment with TXAS specific inhibitors resulted in decreased migration 
rate and intercellular adhesion, indicating TXA2 signaling may represent a novel strategy 
for anti-invasive therapies for glial tumors [45]. As mentioned above, TXAS and TP 
especially TPβ were highly expressed in invasive bladder cancer tissues compared with 
their normal paired tissues and correlated with poor prognosis [33, 34]. Ectopic 
expression of TPβ in normal bladder epithelial cell line significantly increased migration 
and invasion [34]. The mechanistic study revealed that TP receptor agonist stimulated 
bladder cancer cell migration through both β-arrestin 2 and Gα12 signaling [34]. 
Moreover, TXAS was also implied to be involved in lung cancer metastasis since TXAS 
inhibitor significantly inhibited pulmonary metastasis in mice intravenously injected 




        In order to grow beyond a certain size and to metastasize, tumors need to recruit 
blood vessels to supply oxygen and nutrients. Angiogenesis is the growth of new blood 
vessels from the existing vasculature and is critical for tumor growth and progression.  
TXA2 modulates angiogenesis at different levels.    
        The expression of TXAS was reported to positively correlate to the production of 
angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast 
growth factor (bFGF) in NSCLC [47], indicating TXA2 may enhance angiogenesis, 
thereby accelerating cancer progression. It was demonstrated that TXA2 induced 
expression of VEGF at both mRNA and protein levels in human lung cancer cells. 
Xenografts of A549-TPα cells increased tumor growth rate and vascularization in nude 
mice [37]. Similar results were also obtained from mice inoculated with C26-TXAS cells, 
which are colon adenocarcinoma cells overexpressing exogenous TXAS [48].   
        TXA2 not only has an autocrine effect on tumor cells to release pro-angiogenic 
factors but also directly act on endothelial cells to promote angiogenesis. The pro-
angiogenic factor bFGF and VEGF stimulated the release of TXA2 from endothelial cells 
up to five-fold [46].  TXA2 mimetic U46619 increased endothelial cells migration and the 
inhibitors of TXAS or antagonist of TP blocked bFGF-induced endothelial cells 
migration in vitro and angiogenesis in vivo [46, 49].  Furthermore, treatment of rat aortic 
explants with U46619 significantly enhanced vessel sprouting whereas treatment with 
TXA2 inhibitors showed a significant decrease in vessel sprouting [50], which was not 
rescued by adding VEGF indicating the essential contribution of TXA2 to angiogenesis.  
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         There are numerous studies indicating the role of TXAS, TXA2 and TP in cancer 
progression, and some mechanisms were also revealed in these studies. However, 
regarding the relationship between TXA2 and cancer invasion and metastasis, most of 
these reports are focused on TXAS.  As shown in Figure 1, prostaglandins and 
thromboxane synthetic pathways are complex and influenced by each other. Inhibition of 
TXAS will increase the production of other PGs which either as tumor suppressor (PGI2) 
or promoter (PGE2). Therefore the approach of inhibiting TXAS will result in other 
effects related with the generation of other PGs.  In this dissertation, I used approaches 
that only interfere with TXA2/TP and no other PGs pathways to identify the key 
components of TXA2/TP signaling-promoted cancer invasion, and thus providing 
additional mechanisms for validating TP as a target of intervention to block cancer 
invasion and metastasis.  
1.4 Cancer invasion and metastasis  
        Prevention of cancer metastasis is the major goal of cancer therapy as metastasis is 
account for 90% of death in patients with malignancy. The process that cancer cells break 
off from a primary tumor and spread to other parts of the body is metastasis. Metastasis is 
a very complicated process still not well understood. The classic view of cancer 
metastasis consists a complex succession of cell-biological events starting from epithelial 
cells in primary tumors: (1) invade locally into surrounding extracellular matrix (ECM) 
and the host stroma, (2) intravasate into blood and lymph vessels, (3) survive in the 
circulation and transport through the vasculature, (4) arrest in the capillary beds of distant 
organs, (5) extravasate from vessels into the parenchyma of distant tissues, (6) survive in 
the new microenvironment and establish micrometastases, and (7) proliferate within the 
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organ parenchyma, therefore generating the metastatic colonization and clinically 
detectable macroscopic metastases (Figure 5) [51]. To complete all the metastatic 
processes, cancer cells have to overcome the physiological barriers in each step. This is 
regulated by molecular pathways operating within cancer cells and also the cooperation 
between stroma cells and cancer cells. Each step in the metastatic cascade can be rate 
limiting. Here, we only focus on the initial step of metastasis, local invasion.  



















        Invasion is a process that cancer cells break away from a primary tumor and enter 
the surrounding tissues. During this process, cancer cells lose cell-cell adhesion, acquire a 
migratory phenotype, penetrate the basement membrane, and invade the interstitial matrix 
(Figure 6) [52].  
        Most solid tumors are derived from epithelial cells which are closely attached to 
each other to form a rigid cell sheets. Cadherins, a family of intercellular adhesion 
molecules, play important roles in keeping cells together.  E-cadherin, one subtype in this 
family, has been demonstrated to play a crucial role in epithelial cell-cell adhesion.  It has 
been implicated in carcinogenesis due to its partially or entirely missing in human 
epithelial cancers [53]. Loss of E-cadherin resulting in tumor cells invasion has been 
shown in E-cadherin knockout mouse models [54].  Indeed, repression of E-cadherin is a 
critical molecular feature of epithelial-mesenchymal transition (EMT), which is a 
biological program defined by the loss of epithelial characteristics and the acquisition of 
a mesenchymal phenotype. Cells that have undergone EMT often disassemble their 
adherens junctions, lose polarity, acquire spindle-shaped morphology, enhance migration, 
induce mesenchymal proteins, as well as various proteinases. Therefore, EMT is a critical 
















Figure 6. Cancer cell invasion process 
At the onset of invasion process, cancer cells lose E-cadherin-dependent cell-cell 
adhesion, acquire a migratory phenotype, penetrate the basement membrane, and invade 
the interstitial matrix.  
 
 
        Loss of adhesion enables cells to move, whereas loss of the basement membrane 
ultimately allows the invasion of cancer cells into the stromal compartment. Basement 
membrane is a thin ECM layer which separates the epithelium from the interstitial 
stroma. In addition to the structural function, basement membrane also plays an important 
role in signal transduction through integrin-mediated cell-marix interaction, leading to the 
alterations in cell polarity, proliferation, survival, invasion and metastasis[52]. To breach 
the basement membrane and invade the interstitial matrix cancer cells release a variety of 
proteolytic enzymes such as collagenases, cathepsins, and plasminogen activators. 
Among these enzymes, matrix metalloproteinases (MMPs) play major roles in proteolytic 
degradation of basement membrane and ECM remodeling due to their ability to degrade a 
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multitude of substrates. MMPs also release growth factors sequestered in the ECM to 
stimulate cancer cell proliferation and angiogenesis [56, 57].   
        Once cancer cells have dissolved basement membrane, they invade the stroma where 
they encounter a variety of stromal cells including fibroblasts, endothelial cells, and 
various bone marrow-derived cells (BMDCs) such as myeloid cell-derived suppressor 
cells, mesenchymal stem cells, macrophages, as well as other immune cells [58]. These 
stromal cells in tumor microenvironment secrete growth factors or proteases that further 
enhance tumor cells proliferation, invasion and metastasis.  For example, tumor 
associated macrophages (TAMs) produced EGF to activate EGFR signaling in the 
malignant epithelial cells, thereby enhancing their invasive potential [59]. Similarly, the 
expression of cathepsin and MMP-9 proteases by TAMs further augments carcinoma 
cells invasion [60, 61].  More detailed background about TAMs and the roles they played 
in cancer invasion will be introduced later.   
1.5 Matrix metalloproteinases (MMPs) in cancer invasion and metastasis 
        As mentioned above, MMPs are the major players in degrading basement membrane 
and ECM, the physiological barriers that must be overcome by cancer cells for successful 
invasion and metastasis. MMPs are a family of zinc-dependent proteases which contain 
24 members in human, and collectively, they are capable of degrading all known ECM 
components.  Elevation of MMPs has been found in various cancer types and considered 
as biomarkers for poor prognosis [62]. Therefore, understanding molecular pathways 
leading to upregulation of MMPs in cancer is important for the treatment of cancer 
invasion and metastasis.   
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1.5.1 Association of COX -2 and MMPs in cancer invasion and metastasis    
        COX-2, the key enzyme in TXA2 synthetic pathway, was found to be associated 
with MMPs expression to increase metastasis of several types of cancer.  Byun et al. 
reported that there was a positive correlation between COX-2 and MMP-2 expression, 
and the latter might contribute to cancer progression and reduced survival in NSCLC 
patients [63].  COX-2 inhibitor blocked liver metastasis of colorectal cancer cells due to 
suppression of MMP-9 activity [64].  Moreover, inhibition of COX-2 decreased invasion 
and metastasis in breast cancer via decrease in multiple MMPs [65].  In light of these 
findings, no reports were found to describe the relationship between TP and MMPs in 
cancer progression.  Since TXA2 is one of the major prostanoids downstream of COX-2 
pathway, it is proposed that TXA2 may also mediate cancer cell invasion through 
upregulation of MMPs.   
        MMP-1, the first member of MMPs family to be identified, was found to be 
associated with poor prognosis in a wide variety of advanced cancers including lung 
cancer [66, 67]. Low levels of both MMP-1 and COX-2 were positively correlated with 
survival in NSCLC [68].   Most recently, protease-activated receptor 1(PAR1) was 
identified as a novel substrate for MMP-1[69]. MMP-1/PAR1 axis has been shown to 
mediate invasion of breast cancer and melanoma cells [69, 70] providing further evidence 
for the role of MMP-1 in cancer invasion and metastasis.  
        In this dissertation, I mainly focused on the role of MMP-1 in TP-mediated cancer 
cell invasion, and further to identify the signaling pathways involved in TP-mediated 
MMP-1 expression which serve as a model for TP-mediated regulation of other MMPs.   
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1.5.2 MMPs regulation 
        MMPs are synthesized as pro-zymogens which are either secreted into extracellular 
space or in membrane-bound form.  MMPs activity can be regulated at multiple levels 
such as activation by cell surface proteins [71] and inhibition by tissue inhibitors of 
metalloproteinases (TIMPs) [72]. However, aberrantly high expression of MMPs has 
major impact on ECM turnover, thereby contributing to the pathology of diverse diseases 
including cancer, and this is predominantly controlled at the levels of MMPs gene 
expression.   
        Based on the compositions of cis-acting elements in their promoters, MMPs have 
been roughly grouped into three categories [73]. Group 1 consists of the majority of the 
MMPs: MMP-1, 3, 7, 9, 10, 12, 13 and 19 which contain a TATA box and an AP-1 site 
in the proximal region of their promoters. Group 2 consists of MMP-8 and MMP-11, 
which contain a TATA box but lack the AP-1 site. Group 3 consists of MMP-2 and 
MMP-14 which lack both the TATA box and the AP-1 site. This classification indicates 
the types of extracellular signaling that activate them.  
        Indeed, a variety of signal transduction pathways are involved in MMPs gene 
regulation [74]. The mitogen activated protein kinase (MAPK) pathways including ERK 
pathway as well as the p38 MAPK and c-Jun N-terminal kinase (JNK ) pathways regulate 
expression of several MMPs genes such as MMP-1[75-77], MMP-3[78, 79], MMP-9 [80, 
81] and MMP-13[82]. Nuclear factor-kappaB (NF-κB) pathway can impact MMPs gene 
expression through direct transactivation or induction of intermediary genes. For 
example, RelA, A subfamily of NF-κB proteins, may activate NF-κB co-factor Bcl-3 
expression [83], and that Bcl-3 in turn activates MMP-1 gene expression [84]. MMP-9 
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promoter contains a canonical NF-κB binding site that could directly bind RelA to 
activate gene transcription [85].  Other signaling pathways such as Smad and STAT 
regulate MMPs gene expression via interaction with other transcription factors.  Smad3 
interacted with JunB and Runx-2 for TGF-β-induced MMP-13 expression is an example 
of this mechanism [86].  STAT3 does not directly bind the MMP-1 promoter, but it can 
augment MMP-1 transcription through induction of AP-1 proteins such as c-fos [87]. In 
contrast to STAT3, STAT1 mediates interferon (INF)-γ -repressed IL-1β induction of 
MMP-13 via sequestration of the transcriptional co-activator CBP/p300 [88]. In 
summary, MMPs gene regulation is a complex process which involves the integration of 
multiple signaling pathways and transcriptional factors.         
1.6 Protease-activated receptors (PARs) and cancer progression and invasion 
1.6.1 PARs and their activation 
         Protease-activated receptor (PAR) is a unique family of GPCR, which consists of 
four members: PAR1, PAR2, PAR3 and PAR4. Each PAR carries its own ligand, which 
is in a masked state until exposed by receptor cleavage. The exposed ligand binds 
intramolecularly to the receptor to trigger multiple signaling cascades. A certain proteases 
can activate PARs. Thrombin can cleave and activate PAR1, PAR3 and PAR4. PAR2 is 
cleaved by trypsin, mast cell tryptase, tissue factor/factor VIIa/factor Xa but not by 
thrombin. Small synthetic peptides corresponding to the tethered ligand domain are 
developed as PAR agonist peptides (PAR-APs), which activate PARs without receptor 
cleavage [89, 90] (Figure 7).   
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         PARs mediate a wide variety of physiological and pathophysiological responses 
including coagulation, inflammatory responses, repair, mucosal protection, neurogenic 
inflammation and pain transmission, etc.  The role of PARs in cancer progression has 














Figure 7. Mechanism of activation of proteinase-activated receptors by proteinases 
Four members of the family: PAR1, PAR2, PAR3 and PAR4, proteinases responsible for 
PARs activation (in blue) and tethered ligand peptidic sequences (red boxes) that can be 




1.6.2 PAR1 and cancer progression and invasion  
        PAR1 is overexpressed in a wide range of cancers, such as melanoma, high-grade 
gliomas, colon cancer, prostate cancer and invasive breast cancer. The contributions of 
PAR1 to cancer invasion and metastasis have been demonstrated in many studies. Even-
Ram et al. showed a direct correlation between the levels of PAR1 expression and the 
degree of invasiveness in established breast cancer cell lines as well as in human breast 
tissue specimens [92]. Transfection of functional PAR1 is sufficient to promote the 
invasion of MCF-7 cells, which are normally noninvasive breast carcinoma cells without 
PAR1 expression, both in vitro and in a xenograft nude mouse model [69]. In addition, 
antisense of PAR1 reduced the invasiveness of aggressively metastatic breast cancer cells 
[69, 92].   
        Recently, the identification of novel PAR1 activating protease, MMP-1, connects 
the extracellular proteolytic activity with membrane receptor-mediated signal in cancer 
progression.  MMP-1/PAR1 axis has been identified to mediate invasion and metastasis 
of breast cancer [69, 93], melanoma [70] and ovarian cancer [94, 95]. Whether MMP1 
targets other PARs or other MMPs cleave PARs remains open for further investigation.  
1.6.3 PAR2 and cancer progression and invasion  
        PAR2 is another dominant PAR mediating protease signaling in tumor cells. Factor 
VIIa and Xa-induced migration and invasion of invasive breast cancer cells is mediated 
by PAR2 [96, 97]. Using mouse mammary tumor virus-polyoma middle T (PyMT) 
mouse model which mimics important aspects of human breast cancer pathology, 
Versteeg et al. demonstrated that PAR2, not PAR1, plays a critical role for spontaneous 
breast cancer development [98].   
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        PAR2 promotes cancer progression through various mechanisms.  Activation of 
PAR2 induces proliferation of gastric and colon cancer cells through trans-activation of 
EGFR and ERK1/2 activation mechanisms [99, 100]. PAR2 mediates migration of breast 
cancer cells through β-arrestin-dependent ERK1/2 activation [101]. TF-VIIa-PAR2 
signaling in breast cancer cells induced a broad array of pro-angiogenic factors and 
immune regulators such as VEGF [102], Cyr61, VEGF-C, CTGF, CXCL1, IL-8, CSF1 
and CSF2 [103]. Upregulation of IL-8 by TF-VIIa-PAR2 signaling resulted in breast 
cancer cell migration and invasion [97].  PAR2 agonist-triggered IL-8 release may also 
promote pancreatic cancer progression [104].  
        Since PARs participate in regulation of inflammatory cytokines and related genes, 
which are important for cancer progression. The question that whether PARs signaling 
could recruit inflammatory cells, such as monocyte/macrophages, neutrophils, and T cells 
to modulate cancer growth and metastasis needs to be addressed. PAR1-mediated 
production of chemokine monocyte chemoattractant protein 1(MCP-1) is critical for 
natural killer cells and macrophages recruitments in a mouse heart-to-rat transplant model 
[105]. Activation of PAR1or PAR2 induces MCP-1 expression was also reported in 
human lung carcinoma cell line A549 [106].  These studies suggest that MCP-1 may link 




1.7 Monocyte chemoattractant protein 1(MCP-1) and cancer progression and 
metastasis 
1.7.1 MCP-1 discovery 
        MCP-1(nomenclature name is chemokine (C-C motif) ligand 2, CCL2; alternative 
name are MCAF, JE, SMC-CF, HC-11) is a small cytokine belonging to CC chemokine 
family. MCP-1 was initially discovered as the product of the JE gene from murine 
fibroblasts treated with PDGF [107, 108]. Human MCP-1 protein was isolated and 
purified by two groups in 1989 [109-111], they identified this novel cytokine as the 
product of human JE gene [112, 113].  Human MCP-1 is produced as a protein precursor 
which contains a 23 amino acid of signal peptide. The mature MCP-1 comprises 76 
amino acids corresponding for a predicted molecular weight of 8.7 kDa. However, SDS-
PAGE analysis showed that MCP-1 secreted by human cells migrated as 13 and 15 kDa 
proteins [110]. This may be due to the post-translational modification of MCP-1with O-
linked carbohydrate processing [114]. Nearly half of murine MCP-1 protein displays a 
molecular weight of 30-35 kDa due to high glycosylation.  
1.7.2 MCP-1 regulation  
       MCP-1 is a small inducible chemokine encoded by CCL2 gene, which located on 
human chromosome 17.  A variety of cytokines, such as platelet-derived growth factor 
(PDGF) [115], tumor necrosis factor alpha (TNFα) [116], interferon gamma (IFN-γ) 
[117], and IL-1β [118, 119] can induce MCP-1 expression at transcriptional level.  
        Several cis-acting transcription regulatory elements binding sites on MCP-1 
promoter have been mapped (Figure 8). The distal part of MCP-1 promoter contains two 
NF-κB binding sites, which are required for TNFα-induced MCP-1 expression, but not 
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essential for PDGF-stimulated expression [115]. The proximal part of MCP-1 promoter is 
essential for all aspects of MCP-1 gene regulation and is sufficient for PDGF- and INF-γ-
induced expression [115, 117]. The proximal region contains a GC box, which binds 
transcription factor SP1 to regulate both constitutive and stimulus-induced transcriptional 
activity. Two AP-1 and one NF-κB sites also sit in the proximal region. They are 
responsible for endothelin-1-mediated MCP-1 regulation in human airway smooth 






Figure 8. Transcription factors in MCP-1 promoter 
 
 
1.7.3 MCP-1/CCR2 expression and activity 
        MCP-1 is expressed by many cell types and organs either constitutively or after 
stimulation by cytokines or growth factors.  Both in vitro and in vivo studies 
demonstrated that MCP-1 is a potent chemoattractant for monocytes, T lymphocytes, 
nature killer (NK) cells, basophils, and dendritic cells [121].  MCP-1 exerts its effects 
through its receptor CCR2. There are two isoforms of CCR2, named CCR2A and 
CCR2B, which differ only in their C-terminal tails. CCR2 expression is not as broad as 
MCP-1. CCR2A mainly expresses by mononuclear cells and vascular smooth muscle 
cells. CCR2B is the predominant isoform expressed by monocytes and activated NK 
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cells.  MCP-1 is very specific and binds only to CCR2 with a high binding affinity (Kd ˂ 
1nM). The other MCPs (MCP-2, MCP-3, and MCP-4 in human, MCP-2, MCP-3, and 
MCP-5 in mouse) also bind CCR2 with high affinity leading to the uncertainty of 
whether MCP-1 is essential in recruitment of monocytes in vivo.  A study using MCP-1-
deficient mice showed that loss of MCP-1 alone is sufficient for impairment of monocyte 
trafficking in vivo and other MCPs do not increase to compensate for MCP-1’s absence 
[122] suggesting the critical role of MCP-1 in monocytes recruitment.  
1.7.4 MCP-1 and cancer progression and metastasis 
        MCP-1 is expressed by a variety of cancer types suggesting its role in cancer 
progression. MCP-1 promotes tumorigenesis and metastasis through two mechanisms: (1) 
directly acts on tumor cells to influence cancer behavior, and (2) indirectly acts on tumor 
microenvironment by recruiting macrophage to tumor cells, therefore promoting tumor 
growth, angiogenesis and metastasis.   
1.7.4.1 Direct effects 
        Direct effects of MCP-1on tumor cell physiology have been demonstrated in 
prostate cancer cells. Both MCP-1 and CCR2 were found to be expressed by prostate 
cancer cell lines, including LNCaP, C4-2B and PC3 cells.  MCP-1 induces proliferation 
and invasion of PC3 and LNCaP cells in both autocrine and paracrine manners [123, 
124]. Suppression of tumor- and host-derived MCP-1 by its neutralizing antibody 
attenuates prostate tumor growth and metastasis in vivo [124].  Moreover, CCR2 
expression is correlated with the malignant state of prostate cancer.  The more aggressive 
the cancer cells, the higher levels the CCR2 expression [125].  In addition to prostate 
cancer, MCP-1 also induces migration of breast cancer cell MCF-7 and malignant glioma 
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cells in vitro [126, 127].  Multiple myeloma (MM) cells, malignant plasma cells in bone 
marrow, express a high level of CCR2 compared with normal plasma cells [128]. CCR2 
mediates migration of MM cells to osteoclasts which generate high levels of MCP-1 and 
several other MCPs. Osteoclasts in turn produce various growth factors, such as insulin-
like growth factor1 (IGF-1), interleukin-6 (IL-6) and a proliferation-inducing ligand ( 
APRIL) to support MM cells survival, growth and drug resistance [129].  
1.7.4.2 Indirect effects  
        A large body of research has indicated the indirect effects of MCP-1 on cancer 
progression. Actually, MCP-1 is originally isolated from tumor-derived chemoattractants 
[111] which mediate the infiltration of macrophage into tumors to either suppress or 
enhance tumor growth. MCP-1 associated with mononuclear cell infiltrate inhibiting 
tumor growth has been reported [130, 131]. However, the anti-tumor effect of MCP-1 is 
unlikely to be its major influence on tumor regulation based on the biological and 
epidemiological considerations [132].  
        There is growing evidence supported the notion that MCP-1-mediated macrophage 
infiltration promotes tumor progression.  In a clinical study, the levels of MCP-1 in 
primary breast cancers were found to be correlated significantly with the accumulation of 
tumor associated macrophages (TAMs) [133], which are capable of affecting tumor 
progression in a variety of aspects.  After 6 years of follow up, those breast cancer 
patients with high levels of MCP-1 had a significantly shorter relapse free survival.  This 
clinical association might be explained by mechanistic studies using mouse model that 
MCP-1 secreted by breast tumor cells recruits inflammatory monocytes which produce 
VEGF to promote tumor cells extravasation and lung metastasis [134, 135]. MCP-1 was 
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reported to directly influence prostate cancer growth and metastasis [123].  It also can 
enhance prostate tumor growth and angiogenesis indirectly by recruitment of monocytes 
and TAMs into the tumor microenvironment [136].  Moreover, tumor cells derived from 
renal cancer recruit tumor-infiltrating lymphocytes (TIL) by secreting MCP-1 and IL-8, 
which suggests MCP-1’s indirect effect on renal cancer progression [137]. CC 
chemokines including MCP-1 and MIP-1b were found to be associated with macrophage 
infiltration in human NSCLC tumors. Those patients with recurrence of disease had 
higher macrophage infiltration in their initial tumors [138].  In addition to tumor cells 
themselves, tumor associated stromal cells such as endothelial cells, fibroblasts and 
macrophages also produced a significant amount of MCP-1 to increase TAM infiltration 
and maintain inflammation, therefore promoting tumor progression [139, 140]. The two 












Figure 9. Mechanisms of MCP-1 on cancer progression 
29 
 
1.8 Tumor associated macrophages (TAMs) and cancer invasion 
        Solid tumors are comprised of not only malignant cells but also many other non-
malignant cell types including fibroblasts, endothelial cells, and immune cells such as 
neutrophils, dendritic cells, macrophages, eosinophils and mast cells [141, 142]. 
Macrophages are the most abundant immune infiltrates in tumors and these macrophages 
are termed as tumor associated macrophages (TAMs). TAMs are mostly derived from the 
peripheral blood monocytes and recruited by tumor cells secreted chemokines and growth 
factors such as CCL2 (MCP-1), CCL3, CCL4, CCL5, CSF-1 and VEGF [143, 144].  
1.8.1 TAMs as prognostic marker for human cancer  
        A large body of clinical evidence showed that increased accumulation of TAMs are 
associated with poor prognosis for a variety of cancer types including prostate, breast, 
ovarian, cervical, bladder, endometrial, and esophageal cancers [133, 145-149].  For lung 
cancer, the data obtained from clinical studies seem controversial.  Two groups reported 
that higher levels of macrophages were significantly correlated with lower survival rates 
for patients with NSCLC [138, 150]. However, the results reported by Toomey et al. 
showed that there was no association between macrophages infiltration and prognosis of 
NSCLC [151]. These conflicting observations may derive from the different methods 
used to assess macrophage infiltration, or the different tumor grades and stages in these 
studies.  In addition, macrophages within different locations of tumor may have different 
effects on the outcome of patients.  Welsh et al. found that the numbers of stroma 
macrophages were negatively associated with NSCLC patient’s survival time, whereas 
the numbers of tumor islet macrophages were positively associated with patient’s 
survival time [152].  Indeed, the impact of macrophages on tumor is more complicated.  
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Macrophages have been classified into two major groups: M1 and M2 macrophages. M1 
macrophages possess pro-inflammatory properties, whereas M2 macrophages have anti-
inflammatory phenotype and promote tumor progression [153].  TAMs have been 
identified as M2 macrophages [154].  Within the tumor islet, both M1 and M2 
macrophages could be present. Those macrophages associated with favorable outcome in 
NSCLC patients were identified as M1 macrophages [155] . M2 macrophages may 
function the opposite way. Zeni et al. [156] reported that the percentage of IL-10-positive 
macrophages within tumor islet was higher in patients with late stage of NSCLC and 
lymph node metastasis compared with those patients with lower stage of NSCLC and 
without metastasis, and these macrophages also predicted the worse overall survival rate. 
High expression of IL-10 is one of the characteristic of M2 phenotype [157], thus this 
study suggested that these macrophages behaved as M2-polarized TAMs, and thereafter 
promoted progression of NSCLC.   
1.8.2 TAMs enhance invasiveness of cancer cells 
        TAMs promote cancer progression in many aspects, including stimulation of tumor 
growth, induction of angiogenesis, and promotion of tumor cells migration and invasion.  
TAMs enhancement of cancer cells invasion through several mechanisms.  First, 
macrophages-derived proteases could disrupt the extracellular matrix, and therefore allow 
cancer cells to invade the surrounding tissues.  For example, TAMs secreted cathepsin B, 
one of cysteine-type lysosomal proteases, to promote lung metastasis of breast cancer as 
well as the invasion of pancreatic tumor in vivo [60, 158].  Other proteases such as MMP-
9 [61, 159] and urokinase-type plasminogen activator [160], a serine protease, are also 
secreted by TAMs, and both of them are involved in TAM-enhanced cancer cells 
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invasion.  In addition to proteases, TAMs also produce growth factors such as EGF and 
TGFβ which directly act on carcinoma cells to promote their invasion [59, 161]. 
Furthermore, TAMs could increase invasion of cancer cells by inducing the epithelial-
mesenchymal transition (EMT). Lin et al. reported that activated macrophages may 
stimulate the migration and invasion of HepG2 human hepatocellular carcinoma cells via 
c-Src and EGFR-dependent downregulation of E-cadherin and β-catenin at the adherens 
junctions [162]. Moreover, TAMs interact with cancer cells to upregulate a wide array of 
genes in cancer cells, such as IL-6, NF-κB, ICAM-1, MMP-1, MMP-9, VEGF-A, VEGF-
C, etc. and these genes are involved in angiogenesis, growth, adhesion, invasion, and 
metastasis [163].   In return, macrophages could also be activated by cancer cells to 
secrete growth factors, cytokines and proteases, subsequently enhanced cancer invasion 
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2. Purpose of this dissertation 
        TXA2-TP signaling axis is involved in multiple steps of cancer progression 
including cancer invasion and metastasis.  Therefore, the purpose of this dissertation is to 
identify novel cellular and molecular mechanisms by which TP mediates cancer cell 
invasion.  I am particularly interested in identifying key molecular mediators associated 
with TP-mediated invasion of lung cancer cells and with specific focus on the 
investigation of TP-mediated signal transduction pathways leading to the expression of 
some of these molecules.  Another purpose is to explore the interactions and relationship 
among these mediators and how they exert their functions in facilitating TP-mediated 
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3. Materials and methods 
3.1 Reagents and antibodies 
        I-BOP, SQ29548, PGD2, PGE2 and PGF2α were from Cayman Chemical (Ann 
Arbor, MI). LY294002, GF109203X and SP600125 were from Calbiochem (San Diego, 
CA). Phorbol-12-Myristate-13-Acetate (PMA), U0126, SB203580 and MG132 were 
from Alexis Biochemicals (San Diego, CA). SCH79797 was from Tocris Bioscience 
(Ellisville, MO).  ENMD-1068 was from Enzo Life Sciences (Farmingdale, NY).  
Agonist peptides of PARs: PAR1, TFLLR-NH2; PAR2, SLIGRL-NH2; PAR3, TFRGAP-
NH2; PAR4, GYPGQV-NH2, as well as antagonist peptide of PAR4, trans-cinnamoyl-
YPGKF (tc-Y-NH2) were supplied by Peptides International (Louisville, KY).  
Recombinant human MMP-1 and MMP-3 were purchased from PeproTech (Rocky Hill, 
NJ).  MMP-1-siRNA, MMP-9-siRNA, C/EBPβ-siRNA, PAR2-siRNA and control-
siRNA were from Santa Cruz Biotechnology (Santa Cruz, CA).  Cell culture medium, 
heat-inactivated fetal bovine serum (FBS), restriction enzymes, SuperScript II reverse 
transcriptase, penicillin G and Lipofectamine 2000 were supplied by Invitrogen or Gibco 
(Carlsbad, CA). TransIT-2020 Transfection Reagent was from Mirus Bio LLC (Madison, 
WI). Site-directed mutagenesis kit was from Stragene (La Jolla, CA). Centrifugal filter 
devices were purchased from Millipore (Billerica, MA). CytoSelect 96-well cell 
migration and invasion assay kits were supplied by Cell Biolabs (San Diego, CA). TRI 
Reagent, trypsin, soybean trypsin inhibitor, RS-102895, mithramycin A, geldanamycin 
and other biochemicals and chemicals were from Sigma-Aldrich (St. Louis, MO).  
pcDNA3-MMP-9 expression plasmid was a kind gift of Dr. R. Fridman of the Wayne 
State University (Detroit, MI).  All lentivirus related plasmids were kind gifts of Dr. 
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Louis Hersh of the University of Kentucky (Lexington, KY). Human MMP-1 promoter 
/luciferase reporter plasmids pGL3-2942 and pGL3-2942∆CEBP were kindly supplied by 
Dr. Matthew P. Vincent of Dartmouth Medical School (Hanover, NH).  Human MCP-1-
CAT reporter plasmid was kindly provided by Dr. Bassel E. Sawaya of Temple 
University (Philadelphia, PA). 
        The primary antibodies used in this study were MMP-1, MMP-3, MMP-9 
(NeoMarkers, Fremont, CA), PAR-2, SP1, E-cadherin, Phospho-ERK1/2, C/EBPβ (Santa 
Cruz Biotechnology, Santa Cruz, CA),  Phospho-c-Jun (Ser73), Phospho-C/EBPβ 
(Thr235), ERK1/2 (Cell Signaling Technology, Danvers, MA), MCP-1 (PeproTech, 
Rocky Hill, NJ), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (generated in 
house). Horseradish peroxidase (HRP)-linked goat anti-mouse and rabbit secondary 
antibodies were supplied by Invitrogen (Carlsbad, CA).  
3.2 Cell lines and culture 
3.2.1 Wild-type cell lines  
        A549, H460 and H157 non-small cell lung cancer cells were maintained in RPMI 
1640 medium. Mouse RAW 264.7 macrophages were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM).  293 FT cells were used for lentivirus production and 
maintained in DMEM supplemented with 0.1mM non-essential amino acids.  All these 
cells lines were from American Type Culture Collection (Manassas, VA ) and grown in 
their corresponding cell culture media with supplemented 10% FBS, 100 U/ml penicillin 




3.2.2 Establishment of A549-TPα and A549-TPβ cell lines 
        TPα and TPβ were cloned into pCSC-SP-PW lentiviral vector, transfected into 293 
FT cells with packaging plasmids, pMDL-gp.RRE, pRSV.Rev and pVSVG using 
Lipofectamine 2000 following the manufacture’s protocol. Similarly, GFP was cloned 
into pCSC-SP-PW vector and used as a control plasmid. The medium was replaced with 
fresh DMEM medium containing 10% FBS after 12 h transfection.  Supernatants 
containing virus particles were collected 36 h after the start of transfection, filtered 
through 0.45 µm filter, and then were used to infect A549 cell line. A549 cells infected 
with virus particles encoding GFP, TPα or TPβ were harvested in three separate pools 
and designated as control A549 cells, A549-TPα and A549-TPβ cells accordingly.  These 
infected cells were cultured until stably expressing the encoding genes.  All these cells 
were maintained in RPMI1640 medium supplement with 10% FBS, 0.1 mg/mL 
streptomycin and 100U/mL of penicillin G at 37°C in a humidified atmosphere of 95% 
air and 5% CO2.   
3.3 Cell treatment and Western blot analysis  
        Cells were plated in 12-well plates to achieve ~ 80% confluence, and then were 
starved in RPMI 1640 medium without FBS for 24 h before stimulation.  For inhibitor 
study, cells were pretreated with the respective inhibitors at working concentrations or 
control (0.1% DMSO) for 30 min in serum-free medium prior to stimulation. After a 
certain time of treatment, cells were collected and lysed with lysis buffer (50 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid, pH 7.4, 150 mM NaCl, 1% Nonidet P-
40, 5 mM NaF, 5 mM pyrophosphate, 1 mM sodium orthovanadate, 10 µg/ml aprotinin, 
10 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride). Conditioned media were 
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collected and concentrated via trichloroacetic acid (TCA)-acetone method.  Western blot 
analysis was carried out as described previously [166].  Briefly, proteins were separated 
in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto polyvinylidene difluoride (PVDF) membrane. Membranes were blocked 
with 5% non-fat milk in Tris-buffered saline at room temperature for 1 h and incubated 
with primary antibodies overnight at 4°C. The membranes were then incubated with 
horseradish peroxidase-linked goat anti-mouse or rabbit secondary antibodies for 1 h at 
room temperature and developed using enhanced chemiluminescence Western blotting 
detection system (Amersham Pharmacia Biotech, Cardiff, UK). All membranes were 
stripped using stripping buffer before reprobing with anti-glyceraldehyde-3-phosphate 
dehydrogenase or anti-ERK1/2 antibodies to ensure equal protein loading.  Band 
intensities were quantified using NIH Image J software and normalized to those of 
GAPDH.  
3.4 Protein precipitation  
        Proteins in media samples were precipitated by using trichloroacetic acid (TCA)-
acetone method.  Briefly, TCA was added to media at a final concentration of 10%. 
Proteins were precipitated for 4 h on ice.  Precipitated protein was centrifuged at 5,000 x 
g for 30 min, washed three times in cold acetone, and air dried. Pellets were frozen at -
80°C until analyzed.  
3.5 Reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNA was isolated from cells using the TRI Reagent and reverse-transcribed 
using the SuperScript II reverse transcriptase following the manufacturer’s instructions.   
PCR conditions were 2 min at 95°C followed by 35 cycles (23 cycles for MCP-1 and β-
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actin) of 95°C for 1 min, 50-55°C for 30s, 72°C for 30s. The PCR product of each sample 
was analyzed by electrophoresis in a 1.5% agarose gel and visualized by ethidium 
bromide staining. The primers used in the PCR reactions are summarized in Table1.  
 




TPα            
                   
5’-GAGATGATGGCTCAGCTCCT-3’ (forward) 
5’-CTACTGCAGCCCGGAGCG-3’  (reverse) 
TPβ            
                   
5’-CTCAGCTCCTGGGGATCAT-3’(forward) 
5’-GTCAAATTCAGGGTCAAAGAGCA-3’(reverse) 


























3.6 Zymographic assay 
Media samples were concentrated 20-fold using the centrifugal filter devices, then 
applied to 10% polyacrylamide gel containing 0.1% gelatin (detecting MMP-2, 9) or 12% 
polyacrylamide gel containing 0.1% casein (detecting MMP-1, 3). Samples were 
electrophoresed at 4°C under a non-reducing condition. The gel was washed with 2.5% 
Triton X-100 for 30 min twice at room temperature to remove the SDS and incubated in 
the developing buffer [100 mM Tris-HCl (pH 8.0), 5 mM CaCl2, 0.05% 23 lauryl ether 
(Brij-35)] at 37°C for 36 h. Gelatinolytic and caseinolytic proteinase activities were 
revealed by coomassie blue staining.  
3.7 Conditioned media and activation of MMPs 
        A549-TPα cells were plated into 10 cm dishes to achieve ~ 80% confluence next 
day, then media were switched to 10 ml serum-free RPMI1640. After 24 h starving, cells 
were treated with vehicle (0.1% ethanol) or 50 nM I-BOP for another 24 h. Then, 
conditioned media were collected and passed through 30 kDa and 10 kDa centrifugal 
filters sequentially to separate MMPs and MCP-1(MCP-1 molecular weight is 13-15 
kDa). The remains on each filter were resolved in 1.5 mL serum-free medium and stored 
at -80°C until used. MMPs in conditioned media were activated using 10 µg/mL trypsin 
for 1 h at 37°C, followed by adding 40 µg/mL soybean trypsin inhibitor to neutralize the 
trypsin.  
3.8 Transient transfection   
         A549-TPα cells were transfected with pcDNA3 or pcDNA3-MMP-9 expression 
plasmid using Lipofectamine 2000 (Invitrogen) according to manufacturer’s instruction. 
Media were collected for further use after transfection for 48 h.   
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3.9 Small interfering (si)-RNA treatment 
         A549-TPα cells were transiently transfected with control siRNA or C/EBPβ, MMP-
1, MMP-9 siRNA at concentration of 50 nM using Lipofectamine 2000.  Cells were 
treated with siRNA for 24 h prior to stimulation by 50 nM I-BOP for another 24 h. For 
PAR-2 knockdown experiment, control A549 cells were transiently transfected with 
control siRNA or PAR2-siRNA at concentration of 100 nM using Lipofectamine 2000. 
Cells were treated with the siRNA for 72 h prior to stimulation by MMP-1 or conditioned 
media for another 16 h.  
3.10 Real-time PCR analysis of MCP-1 mRNA 
        The real-time PCR was performed with human MCP-1 and β-actin (as an internal 
standard)-specific primers (Table 2).  All real-time PCR reactions were carried out in a 
final volume of 50 μL and were performed in duplicate for each cDNA sample in the ABI 
PRISM 7700 Sequence Detection System according to the manufacturer’s protocol. The 
optimized reaction consisted of 25 μL of iTaq SYBRGreen Supermix with ROX, 
0.02 U/μL of Uracil-N-glycosylase, 3 μL of diluted cDNA templates, and 200 nM of each 
specific forward and reverse primer. The PCR protocol was 95 °C for 5 min, followed by 
45 cycles of 95 °C for 15 s and 60 °C for 1 min. Specificity of the amplification was 
checked by melt-curve analysis.  Relative levels of mRNA expression were calculated 
according to Pfaffl method [167].  Individual expression values were normalized by 









5’- ATCCTGAACCCACTTCTGCT-3’ (reverse) 
β-actin 
5’- AGAAAATCTGGCACCACACC-3’ (forward) 
5’- AGAGGCGTACAGGGATAGCA-3’ (reverse) 
 
  
3.11 Promoter constructs and site-directed mutagenesis 
        The MMP-1 promoter construct pGL3-512 was generated from pGL3-2942 by KpnI 
digestion. A site-directed mutagenesis kit was used to mutate the core sequences of three 
AP-1 sites in the pGL3-512 construct: -429m: 5’-TCAGTCA-3’ to 5’-ggAGTCA-3’; -
181m: 5’-TTAATCA-3’ to 5’-ggAATCA-3’; -73m: 5’-TGAGTCA-3’ to 5’-ggAGTCA-
3’.  Human MCP-1-CAT reporter plasmid was reconstructed into pGL3 luciferase 
reporter vector. A site-directed mutagenesis kit was used to mutate the core sequence of 
SP1 binding site in the reconstructed luciferase reporter plasmid: SP1 wild-type (SP1wt), 
5'-CCGCCC-3' to SP1 mutant (SP1m), 5'-CCGggg-3'.  Primers used for generation of 







Table 3. Primers used for generation of site-directed mutagenesis 
NAME SEQUENCE 
-429m forward GCTGGGGGAGCTGAACTGGAGTCAGTACAGGAGCCGAACAGCC 
-429m reverse GGCTGTTCGGCTCCTGTACTGACTCCAGTTCAGCTCCCCCAGC 
-181m forward CGCACACATCTTGTTTGAAGGGAATCATGACATTGCAACACC 
-181m reverse GGTGTTGCAATGTCATGATTCCCTTCAAACAAGATGTGTGCG 
-73 forward GGATGTTATAAAGCAGGAGTCAGACACCTCTGGCTTTCTGG 
-73 reverse CCAGAAAGCCAGAGGTGTCTGACTCCTGCTTTATAACATCC 
SP1m forward CCCTCCTCCTGCTTGACTCCGGGGTCTCTCCCTCTGCCCGC 
SP1m reverse GCGGGCAGAGGGAGAGACCCCGGAGTCAAGCAGGAGGAGGG 
 
 
 3.12 Luciferase assay  
Cells were seeded in 12-well plate and transfected with pGL3-MMP-1 or pGL3-
MCP-1 reporter plasmids using TransIT-2020 Transfection Reagent. After 24 h of 
transfection, cells were incubated with I-BOP or vehicle control (0.1% ethanol) for 
additional 18 h.  Thereafter, cells were collected and further detected by using a 
microplate luminometer (MTX lab systems, Vienna, VA).  The luciferase activity in cell 




3.13 Preparation of nuclear extract 
        Nuclear proteins were prepared as described previously [168]. In brief, A549-TPα 
cells were scraped into cold phosphate buffered saline (PBS) and centrifuged at 1000 rpm 
for 2 min. Pellets were resuspended in buffer A [10 mM HEPES-KOH pH 7.9, 1.5 mM 
MgCl2, 10 mM KCl, 0.5 mM dithiothreitol (DTT) and 0.2 mM phenylmethylsulfonyl 
fluoride (PMSF)] and incubated on ice for 15 min, then centrifuged at full speed in a 
tabletop centrifuge. The nuclear pellets were lysed for 20 min on ice in buffer B (20 mM 
HEPES-KOH, 1.5 mM MgCl2, 420 mM NaCl, 25% glycerol, 0.2 mM EDTA, 0.5 mM 
DTT and 0.2 mM PMSF), and centrifuged for 2 min as above. The supernatant 
containing nuclear proteins was frozen at -80°C until analyzed.  
3.14 Macrophage migration assay 
        RAW 264.7 macrophages migration was assessed by using CytoSelect 96-well cell 
migration assay kit (Cell Biolabs, San Diego, CA) following the manufacturer’s 
instruction.  In brief, ~ 1.0 ×105 cells in serum free medium were seeded onto the top well 
of a Trans-well insert (8 µm polycarbonate nucleopore filters), and the bottom well was 
supplemented with 150 µL  serum free medium or A549-TPα conditioned medium 
through a10 kDa cut-off membrane prepared in 2.7. After 12 h of stimulation, cells that 
had migrated through the filter were detached and dyed with CyQuant GR dye solution. 
The fluorescence was measured at 480/520 nm.  For antibody neutralization study, 150 
µL serum free medium or conditioned medium was incubated with MCP-1 neutralizing 
antibody (5 µg) or isotype control antibody (5 µg) for 2 h at 37°C before added to the 
lower chamber.  For inhibition study, RAW 264.7 cells were incubated with MCP-1 
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receptor (CCR2) antagonist RS-102895 (10 µM) for 30 min before stimulation with the 
conditioned medium. 
3.15 Co-culture experiments 
        For transwell co-culture system, control A549 or A549-TPα cells were plated into a 
six-well culture plate, and RAW 264.7 cells were seeded onto transwell inserts (with a 
0.4 µm pore size) top on another six-well plate. After 24 h, replace the medium of A549 
and RAW cells with fresh serum free medium and move the RAW 264.7 transwell inserts 
onto the six-well plate where A549 cells were seeded.  After 12 h of co-culture, A549 
cells were pictured and collected for RT-PCR analysis.  For direct co-culture, control 
A549 cells which express GFP were plated with or without RAW 264.7 cells into a 12-
well plate and cells were pictured after a certain periods.  Diagrams of two co-culture 
systems were given in Figure 38 and Figure 42. The images of cells were captured using a 
Kodak digital camera under Olympus Tokyo CK inverted microscope. 
 3.16 Invasion assay 
        For I-BOP-induced invasion of A549-TPα and TPβ cells, the invasion assay was 
assessed by using CytoSelect 96-well cell invasion assay kit following the manufacturer’s 
instruction.  In brief, ~ 1.0 ×105 cells in serum free medium were seeded onto the ECM 
protein coated filters, and the lower wells were supplement with medium containing 0.1% 
FBS. I-BOP or GM6001 were directly added to the cell suspension. After incubation for 
24 h, cells that had penetrated through the filter were detached and dyed with CyQuant 
GR dye solution. The fluorescence was measured at 480/520 nM. 
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        For macrophages-promoted invasion of control A549 cells, the invasion assay was 
carried out following the instructions of Cultrex 24-well Transwell BME cell invasion 
assay (Trevigen). Briefly, a 24-well unit with 8 µm polycarbonate nucleopore filters 
(Corning) evenly coated with 100 µL basement membrane extract coating solution 
(Trevigen) at 37 °C for 4 h. Control A549 cells (2×105) expressing GFP and RAW 264.7 
macrophages (1×105) in serum free medium were placed in the upper compartment, and 
50% RPMI 1640 plus 50% DMEM medium supplied with 0.1-0.5% FBS was added to 
the lower compartment. After 24 h incubation, cells that had not invaded were removed 
with a cotton swab. Cells that had invaded the lower surface of the membrane were 
observed under a fluorescence microscope.  Invaded cells in three randomly selected 
fields were counted.  
3.17 Statistical analysis 
The differences between each group were expressed as mean ± SD. Statistical 
significance was assessed by Student’s t test. Differences were considered statistically 













4.1 Overexpression of TP increases invasion of human lung cancer cell A549 
4.1.1 Ectopic expression of TPα and TPβ in A549 cells by lentiviral approach 
        It has been reported that TP agonists can initiate signaling transductions by 
activating endogenously expressed TPα/β in some lung and prostate cancer cells [10, 20].  
In order to explore whether TPα and TPβ function differently we chose to overexpress 
each receptor in human lung A549 cells which express low levels of endogenous TP and 
were shown no response to TP agonist [166].  The approach of using liposome-mediated 
DNA transfection method to increase expression of TP in A549 cells encountered limited 
success.  The approach of using lentiviral vectors to deliver TPα and TPβ cDNAs into 
A549 cells was therefore attempted.  A lentiviral vector harboring GFP was used as a 
control.  Stably transduced clones and populations (cell pools) were collected and 
designated as control A549, A549-TPα, and A549-TPβ cells.  The cell pools were used in 
this study to avoid deriving from the specificity of a single clone.  The expression of TPα 
and TPβ in these cells were determined by RT-PCR.  As shown in Figure 10a, A549-TPα 
cells expressed a significantly higher level of TPα than A549-TPβ and control A549 cells.  
Similarly, A549-TPβ cells expressed highest level of TPβ.  Although there are low levels 
of endogenous expression of TPα and TPβ in A549 cells, their levels are not adequate to 
mediate ERK responses to TP agonist, I-BOP, stimulation.  As shown in Figure 10b, I-
BOP induced significant phosphorylation of ERK in both A549-TPα and A549-TPβ cells 
















 Figure 10. Characterization of A549-TPα and A549-TPβ cells   
(a) RT-PCR identification of over-expressed TPα and TPβ mRNA in A549-TPα and 
A549-TPβ cells. Cells total RNA was isolated.  RT-PCR was carried out as described in 
Materials and methods.   (b) I-BOP-induced phosphorylation of ERK1/2 in A549-TPα 
and A549-TPβ cells. Cells were starved for 24 h before treatment with 50 nM I-BOP at 
indicated time. Western blot was performed as described in Materials and methods. 
GAPDH was used as the protein loading control.  Data are representative of three 




4.1.2 TP agonist induces decreases in E-cadherin levels in A549-TPα and TPβ cells 
        Tumor cell invasion is associated with the disruption of cell-cell adhesion and the 
movement of cells across the ECM. E-cadherin-catenin complex is critical for cell 
adhesiveness and maintenance of normal tissue architecture. Reduction of E-cadherin is 
tightly linked with cell invasion [169]. We examined the effects of TP agonists, I-BOP 
and U46619, on the expression of E-cadherin in our established A549-TPα and TPβ cells. 













Figure 11. Effects of TP activation on E-cadherin expression 
A549-TPα and TPβ cells were starved for 24 h before treated with 50 nM I-BOP or 1µM 
U46619 for another 48 h. The expression of E-cadherin was detected by Western blot 
analysis. Data are representative of three independent experiments. 
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4.1.3 TP agonist induces morphological changes of A549-TPα and TPβ cells  
        To acquire the invasive properties, tumor cells change their epithelial morphology to 
scattered spindle-shaped morphology which is usually associated with the loss of E-
cadherin. In this study, when stimulated with I-BOP, A549-TPα and TPβ cells became 
more scattered and exhibited elongated protrusions, indicating their invasive potential 
(Figure 12).  
 
 








Figure 12. Effects of TP activation on cell morphological changes 
A549 control, A549-TPα and A549-TPβ cells were treated with 10 nM I-BOP or vehicle 
control (0.1% ethanol) for 48h. Cells were visualized with Zeiss Axiovert S100 inverted 
microscope. The images were captured using a Kodak digital camera.  
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4.1.4 TP agonist induces invasion of A549-TPα and TPβ cells 
        Next, we sought to determine whether I-BOP affects A549-TPα and A549-TPβ cells 
invasion by using transwell invasion assay. As shown in Figure 13, I-BOP at 10 nM 
induced significant increase in both A549-TPα and A549-TPβ cellular invasiveness.  









Figure 13. Effects of TP activation on cell invasion 
The invasiveness of A549 control, A549-TPα and A549-TPβ cells under indicated 
concentrations of I-BOP was assayed as described in Materials and methods. Three 
separate experiments and triplicate wells each were performed.  Data are presented as 





4.2 Increased expression of MMPs mediates TP agonist-induced invasion in A549-
TPα cells  
4.2.1 Induction of MMPs expression by TP agonist in both A549-TPα and TPβ cells 
        Induction of MMPs expression by I-BOP in A549-TPα, A549-TPβ and the control 
A549 cells was examined.  Using semi-quantitative RT-PCR, we found that transcription 
of MMP-1, MMP-3, MMP-9 and MMP-10 genes was significantly induced by I-BOP in 
A549-TPα and A549-TPβ cells but not in the control A549 cells (Figure 14a).  I-BOP-
induced increase in secretion of MMP-1 and MMP-9 in the media of A549-TPα and 
A549-TPβ cell cultures was determined by Western blot analysis and zymographic assay 
(Figure 14b. MMP-3 can also be detected by casein zymography and it has a similar 
molecular weight as MMP-1). The expression patterns were comparable for A549 cells 
expressing either TPα or TPβ. Therefore, A549 cells expressing TPα were primarily used 
for in depth study.  
        MMP-1 is the first member of the MMP family being identified and studied in 
greater detail. Many signaling pathways targeted to MMP-1 gene are conserved in other 
MMP genes. Therefore, subsequent studies were focused on TP-mediated MMP-1 
expression and regulation in A549-TPα cells.  I-BOP induced strong and sustained 
expression of MMP-1 mRNA as shown in Figure 15a.  MMP-1 mRNA level increased 
rapidly at 1 h and reached maximum by 8 h following I-BOP stimulation and remained 
high over a 24 h period. The levels of protein expression in conditioned media 
determined by Western blot analysis correlated well with the levels of mRNA analyzed 
by RT-PCR. Dose-dependent study indicated that I-BOP at 1 nM was sufficient to induce 
MMP-1 expression in A549-TPα cells. I-BOP at 50 nM induced the maximal expression 
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(Figure 15b).  The induction of MMP-1, MMP-3 and MMP-10 by I-BOP was also found 
in another lung cancer cell line H460 (Figure 15c) which expresses endogenous TP 
receptors, indicating the induction of MMPs was not simply due to the artificial 
expression of exogenous TP receptors.     
 
  (a) 
    
 
 
              
 
 
Figure 14. Effects of I-BOP on MMPs expression and activity  
(a) I-BOP-induced transcription of several MMPs in A549-TPα and A549-TPβ cells. 
Cells were starved for 24 h before treatment with 50 nM I-BOP for 2 h or 12 h and then 
total RNA was isolated. RT-PCR was carried out as described in Materials and methods.  














Figure14. Effects of I-BOP on MMPs expression and activity 
 (b) I-BOP-induced protein secretions of MMP-1and MMP-9 in A549-TPα and A549-
TPβ cells.  Cells were treated with 50 nM I-BOP for 24 h. Protein expression of MMP-1 
and MMP-9 in the conditioned media were detected by Western blot (upper panel) and 
zymography (lower panel) as described in Materials and methods. MMP-3 can also be 
detected by casein zymography and it has a similar molecular weight as MMP-1. Data are 



















Figure 15. Effects of I-BOP on MMP-1 expression 
(a) Time-dependent effects of I-BOP on MMP-1 expression.  A549-TPα cells were 
treated with 50 nM I-BOP at indicated time. RT-PCR was carried out to identify mRNA 
levels of MMP-1. Densitometric analysis of each band was made. The ratio of MMP-1 to 
β-actin densities at 0 h was normalized to 1.0.  Protein expression of MMP-1in the 
conditioned medium was detected by Western blot analysis.  Data are representative of 












Figure 15. Effects of I-BOP on MMP-1 expression 
(b) Dose-dependent effects of I-BOP on MMP-1 expression.  A549-TPα cells were 
treated with indicated concentrations of I-BOP for 12 h. MMP-1 mRNA level was 
determined by RT-PCR. MMP-1 protein expression in the conditioned medium was 

















Figure 15. Effects of I-BOP on MMP-1 expression 
 (c) I-BOP-induced MMPs expression in H460 cells. H460 cells were treated with 
indicated concentrations of I-BOP for 8 h. MMP-1, MMP-3 and MMP-10 mRNA levels 
and MMP-1 protein expression were determined as described above.  Data are 






4.2.2 Upregulation of MMP-1 is dependent on PKC and MAPK/ERK signaling 
         Signal transduction pathways leading to the expression of MMP-1 were 
investigated using specific inhibitors of signaling molecules. As shown in Figure 16, 
SQ29548, a TP antagonist, blocked totally I-BOP-induced MMP-1 expression at both 
mRNA and protein levels as expected. GF109203X, a PKC inhibitor, attenuated almost 
completely MMP-1 expression at both mRNA and protein levels. LY294002, a 
phosphoinositide-3-kinase (PI-3K) inhibitor, had no inhibitory effect on MMP-1 
induction.    
        Downstream signaling pathway, mitogen-activated protein kinase (MAPK) pathway 
was also examined.  A549-TPα cells were treated with MAPK/ERK inhibitor (U0126), 
stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) inhibitor 
(SP600125) and p38 MAPK inhibitor (SB203580) at previously established inhibitory 
concentrations[166].  Only U0126 completely blocked I-BOP-induced MMP-1 
expression.  Other inhibitors exhibited no effects as shown in Figure 16.  These data 
indicate that upregulation of MMP-1by I-BOP is PKC involved, MAPK/ERK dependent, 























Figure 16. Effects of different inhibitors on I-BOP-induced MMP-1 expression   
A549-TPα cells were treated with various inhibitors for 30 min before incubation with 50 
nM I-BOP for 12 h.  RT-PCR (upper panel) and Western blot (lower panel) were 
performed to determine MMP-1 mRNA level in cells and protein secretion in the 
conditioned medium, respectively. Data are representative of three independent 
experiments.  Inhibitor concentration used: 10 µM SQ29548 (SQ), 10 µM LY294002 
(LY), 0.5 µM GF109203X (GF), 10 µM U0126, 10 µM SB203580 (SB), or 10 µM 





4.2.3 AP-1 as a downstream signal of PKC and MAPK/ERK pathways 
        AP-1, composed of c-Jun and c-Fos families, is a known transcriptional regulator of 
MMP-1 expression[73]. We sought to determine whether PKC and MAPK/ERK 
signaling pathways mediate its activation and therefore regulate TP-induced MMP-1 
expression.  
         Time course studies indicated that c-Jun was strongly activated by I-BOP within 10 
min. The phosphorylation of c-Jun maintained at a maximal level from 30 min to 1 h, and 
remained high even at 2 h (Figure 17a upper panel). The protein expression of c-Fos was 
significantly induced by I-BOP at 1 h and reached a peak level at 2 h (Figure 17a lower 
panel). The rapid activation of c-Jun and c-Fos is consistent with the rapid induction of 
MMP-1 mRNA as shown in Figure 15a. These data suggest that there is a positive 
correlation between I-BOP-induced AP-1 activation and MMP-1 expression. 
        Cells were further treated with PKC and ERK inhibitors to test if they inhibit I-BOP-
induced c-Jun/c-Fos activation. The results showed that PKC inhibitor, GF109203X, 
attenuated significantly c-Jun/c-Fos activation.  ERK inhibitor, U0126, also significantly 
repressed c-Jun activation and totally blocked c-Fos expression (Figure 17b).  
GF109203X had no effect on I-BOP-induced ERK activation suggesting that PKC-
induced activation of c-Jun/c-Fos was not likely to be mediated by MAPK/ERK (Figure 
17b).  PMA, a PKC activator, stimulated the activation of c-Jun/c-Fos providing further 
evidence that PKC was involved in I-BOP-induced AP-1 activation (Figure 17c).  
Although JNK inhibitor partially blocked I-BOP-induced phosphorylation of c-Jun, it has 
no inhibitory effect on I-BOP-induced c-Fos expression (Figure 17d).   
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        To further confirm the involvement of PKC-AP-1 and ERK-AP-1 signal cascades in 
MMP-1 induction, luciferase reporter bearing a fragment of MMP-1 gene promoter which 
contains putative AP-1 sites was employed to examine their roles.  In addition to the 
common ~-70 bp AP-1 site in all Group 1 MMP promoters, the 512 bp length of MMP-1 
promoter construct contains two other putative AP-1 sites at -181 bp and -429 bp [170].  
I-BOP induced a significant increase in luciferase activity which was presumably due to 
the activation of AP-1 proteins.  Site-directed mutagenesis of AP-1 sites at -73 or -181 bp 
of MMP-1 promoter significantly decreased I-BOP-induced luciferase activity.  However, 
mutation of AP-1 site at -429 bp has no effect on I-BOP induction of MMP-1 promoter 
activity indicating that the -73 and -181 AP-1 sites in the proximal region of MMP-1 
promoter are more important for its transcription (Figure 17e).  Inhibitors of PKC and 
ERK significantly attenuated the increase in luciferase activity induced by I-BOP 
stimulation (Figure 17f) supporting the notion that PKC and MAPK/ERK signaling 
pathways may converge at the AP-1 elements to regulate I-BOP-induced MMP-1 gene 





















Figure 17. AP-1 is a downstream signal of PKC and MAPK/ERK pathways 
(a) Time-dependent effect of I-BOP on phosphorylation of c-Jun and induction of c-Fos.  
A549-TPα cells were treated with 50 nM I-BOP at indicated time.  Western blot analysis 



















Figure 17. AP-1 is a downstream signal of PKC and MAPK/ERK pathways 
(b) Effect of PKC and ERK inhibitors on I-BOP-induced phosphorylation of c-Jun and 
the expression of c-Fos.  A549-TPα cells were treated with 0.5 µM GF109203X (GF) or 
10 µM U0126 for 30 min before incubation with 50 nM I-BOP for 30 min (detecting p-c-
Jun and p-ERK1/2) or 2 h (detecting c-Fos), followed by Western blot analysis with 
corresponding primary antibodies to detect  p-ERK1/2, p-c-Jun and c-Fos. Data are 

















Figure 17. AP-1 is a downstream signal of PKC and MAPK/ERK pathways 
(c) Effect of PMA on phosphorylation of c-Jun and expression of c-Fos. Cells were 
treated with 0.5 µM GF109203X (GF) for 30 min before incubation with 100 nM PMA 
for 30 min (detecting p-c-Jun) or 2 h (detecting c-Fos), followed by Western blot analysis 
to detect p-c-Jun and c-Fos. Data are representative of three independent experiments. 
(d) Effect of JNK inhibitor on I-BOP-induced phosphorylation of c-Jun and expression of 
c-Fos. Cells were treated with 10 µM SP600125 (SP) for 30 min before incubation with 
50 nM I-BOP for 30 min (detecting p-c-Jun) or 2 h (detecting c-Fos), followed by 





















Figure 17. AP-1 is a downstream signal of PKC and MAPK/ERK pathways 
(e) AP-1 sites are important for MMP-1 gene activation. Luciferase reporter plasmids 
bearing 512 bp fragment of MMP-1 promoter with wild type or mutated AP-1 sites were 
transfected into A549-TPα cells. After 24 h of transfection, cells were treated with 50 nM 
I-BOP or vehicle control (0.1% ethanol) for additional 18 h. Cell lysates were then 
prepared. Luciferase activity was assayed as described in Materials and methods. Data 
were shown as fold change relative to the vehicle control. Values were means ± SD of 
three independent experiments. Statistical analysis was performed by Student’s t-test.  
















Figure 17. AP-1 is a downstream signal of PKC and MAPK/ERK pathways 
(f) Effect of PKC and ERK inhibitors on I-BOP-induced MMP-1 transcription.  
Luciferase reporter construct containing 512 bp of MMP-1 promoter was transfected into 
A549-TPα cells. After transfection for 24 h, cells were treated with 0.5 µM GF109203X 
(GF) or 10 µM U0126, followed by stimulation with 50 nM I-BOP or vehicle control 
(0.1% ethanol) for 18 h. Luciferase activity was assayed and data were presented as fold 
change relative to the vehicle control. Values were means ± SD of three independent 





4.2.4 C/EBPβ contributes to I-BOP-induced MMP-1 expression  
        I-BOP-induced MMP-1 mRNA did not reach the maximal level until 8 h suggesting 
the possibility that other transcription factors activated later by I-BOP may participate in 
the regulation of MMP-1 transcription.  CCAAT/enhancer-binding protein β (C/EBPβ) 
was identified to contribute to the increase in MMP-1 transcription by IL-1β in 
chondrocytes and A549 cells [171, 172]. To establish whether C/EBPβ play a role in I-
BOP-mediated MMP-1 expression, we first set out to determine the activation of C/EBPβ 
by I-BOP using Western blot analysis. Both the expression and phosphorylation of 
C/EBPβ increased in response to I-BOP stimulation (Figure 18a). The maximal increase 
occurred at 8 h concurrent with the maximal level of MMP-1 mRNA in I-BOP treated 
cells (Figure 15a and Figure 18a), indicating the possibility that C/EBPβ may modulate 
MMP-1 gene expression.  The effect of C/EBPβ inhibition on I-BOP-mediated MMP-1 
expression was then examined. C/EBPβ siRNA at 50 nM significantly knocked down 
C/EBPβ protein expression and phosphorylation in I-BOP treated cells as compared with 
the control siRNA (Figure 18b). The knockdown of C/EBPβ partially blocked I-BOP-
induced MMP-1 mRNA and protein expression, indicating the involvement of C/EBPβ in 
MMP-1 regulation.  
        Furthermore, luciferase reporter assay was used to demonstrate the contribution of 
C/EBPβ to I-BOP-induced MMP-1 transcription. C/EBPβ-binding element is located at -
2,921 bp of human MMP-1 promoter. Deletion mutation of this binding site resulted in 
~70% reduction of basal promoter activity and ~40% decrease in relative fold of I-BOP-
induced promoter activity  compared with the wild type (Figure 18c) indicating that 
C/EBPβ is critical for constitutive and I-BOP-induced MMP-1 expression in A549-TPα 
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cells.  The upstream signaling pathways leading to the activation of C/EBPβ in I-BOP 
treated cells were further examined.  ERK has been reported to phosphorylate C/EBPβ at 
Thr-235 to increase its transcriptional activity [173]. Our Western blot results showed 
that ERK inhibitor, U0126, abrogated both I-BOP-induced expression and 
phosphorylation of C/EBPβ (Figure 18d) suggesting that C/EBPβ-mediated MMP-1 













Figure 18. C/EBPβ contributes to I-BOP-induced MMP-1 expression 
(a) Time-dependent effect of I-BOP on expression and phosphorylation of C/EBPβ.  
A549-TPα cells were treated with 50 nM I-BOP at indicated time. Western blot analysis 
was performed to detect both the expression and phosphorylation of C/EBPβ. Data are 
representative of three separate experiments. 
67 
 














Figure 18. C/EBPβ contributes to I-BOP-induced MMP-1 expression 
(b) Effect of C/EBPβ knockdown on I-BOP-induced MMP-1 expression. A549-TPα cells 
were transfected with 50 nM control siRNA or C/EBPβ siRNA. After transfection for 24 
h, cells were treated with vehicle or 50 nM I-BOP for 8 h (detecting C/EBPβ and p-
CEBP/β) or 12 h (detecting MMP-1). Western blot analysis was carried out to detect the 
expression of C/EBPβ, p-C/EBPβ in cell lysates and the secretion of MMP-1 in the 
conditioned medium. RT-PCR was performed to identify MMP-1 mRNA level as 
described in Materials and methods. Densitometric analysis of each band was made. The 
value of vehicle-treated control was normalized as 1.0.  
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Figure 18. C/EBPβ contributes to I-BOP-induced MMP-1 expression 
(c) C/EBPβ-mediated regulation of MMP-1 promoter activity. A549-TPα cells were 
transfected with luciferase reporter plasmids containing 2,942 bp of MMP-1 promoter 
sequence or same length promoter with an internal deletion of the CEBPβ site located at -
2,921bp. After transfection for 24 h, cells were treated with vehicle control or 50 nM I-
BOP for additional 18 h. Luciferase activity was assayed and data are presented as 
relative light unit (right panel). The relative fold of I-BOP inducibility of wild and mutant 

















Figure 18. C/EBPβ contributes to I-BOP-induced MMP-1 expression 
(d) I-BOP-induced C/EBPβ activation is ERK-dependent. A549-TPα cells were treated 
with 10 µM U0126 for 30 min before stimulation with vehicle control or 50 nM I-BOP 
for 8 h. CEBPβ and p-CEBPβ were assayed by Western blot analysis. Densitometric 
analysis of each band was made. The value of vehicle-treated control was normalized as 







4.2.5 Elevated MMPs promote TP-mediated cell invasion   
        It is believed that MMP family proteins are associated with cancer invasive potential 
[174]. To investigate whether I-BOP could increase cell invasion through upregulation of 
MMPs, in vitro invasion assay was performed.  As shown in Figure 14, I-BOP at 10 nM 
induced significant increase in both A549-TPα and A549-TPβ cellular invasiveness.  
Nonetheless, it has no effect on A549 control cells.  GM6001, a general MMPs inhibitor, 
blocked both basal and I-BOP-induced invasiveness of A549-TPα cells (Figure 19a).  To 
further validate the role of I-BOP-induced MMPs in cell invasion, A549-TPα cells were 
treated with siRNA of MMP-1 and MMP-9 and then analyzed for cellular invasiveness.  
Total inhibition of MMP-1 and MMP-9 expression resulted in ~40% and ~60% decrease 
in invasion, respectively (Figure 19b).  These findings suggest that TP-mediated A549 





















Figure 19. Elevated MMPs promote I-BOP-induced cell invasion   
(a) Effect of MMPs inhibitor on I-BOP-induced invasion of A549-TPα cells. GM6001 at 
10 µM was added in cell suspension before treatment with vehicle control or 10 nM I-





















Figure 19. Elevated MMPs promote I-BOP-induced cell invasion   
(b) Effect of MMP-1 and MMP-9 knockdown on I-BOP-induced invasion.  A549-TPα 
cells were transfected with 50 nM control, MMP-1 or MMP-9 siRNA. After transfection 
for 24 h, cells were resuspended in serum-free media with vehicle control or 10 nM I-
BOP. The mRNA and protein levels of MMP-1 and MMP-9 were measured by RT-PCR 
and Western blot analysis.  Invasion assay was performed as described in Material and 
methods. Three separate experiments and triplicate wells each were performed.  Data are 
presented as invasion relative to the vehicle control-treated cells. * P ˂ 0.05.                
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4.3 MMP-1 released by activation of TP induces expression of MCP-1 from lung 
cancer cells by activation of PAR2           
        In addition to structural components of the ECM, MMPs can cleave non-ECM 
molecules. Protease-activated receptor 1(PAR1) was identified as a novel substrate for 
MMP-1[69].  MMP-1/PAR1 axis has been identified to mediate invasion and metastasis 
of various cancers including breast cancer [69, 93], melanoma [70] and ovarian cancer 
[94, 95].  MCP-1-mediated macrophage infiltration has been demonstrated to contribute 
to cancer metastasis too [132].   Increased release of MCP-1 from A549 cells by 
activation of PAR1 and PAR2 has been reported before [106].  Here we investigated 
whether MMPs released by TP activation may cleave and activate PARs to initiate other 
cascades that involved in cancer invasion and metastasis.  
4.3.1 Conditioned media from TP agonist-treated A549-TPα cells induces the release 
of MCP-1 from A549 cells 
        To determine if MMPs induced by TP agonist can exert autocrine influences on 
cancer cell behavior, we first measured MCP-1 levels in A549 cells treated with 
conditioned media (CM) from A549-TPα cells. As shown in Figure 20, the CM from I-
BOP-treated A549-TPα cells (CM-I-BOP) stimulated significantly the release of MCP-1 
from control A549 cells compared with the CM from vehicle-treated A549-TPα cells 
(CM-Control).  We found that activation of TP induced the expression and release of 
MCP-1 directly from A549-TPα cells (results are presented in 4.4).  To avoid the impact 
of TP on the induction of MCP-1, we used control A549 cells in the following studies.       
 













Figure 20. CM-I-BOP induces release of MCP-1 from A549 cells  
A549 cells were incubated with 100 µL of concentrated conditioned media (CM) as 
described in Materials and methods for 16 h. CM-Control: CM from vehicle (0.1% 
ethanol)-treated A549-TPα cells; and CM-I-BOP: CM from I-BOP-treated A549-TPα 
cells.  Western blot was conducted to determine the release of MCP-1 from A549-GFP 
cells as described in Materials and methods. Densitometric analysis of each band was 





4.3.2 MMP-1 mediates the release of MCP-1 by conditioned media from TP agonist-
treated A549-TPα cells 
         I-BOP induced an increase in protein levels of MMP-1, MMP-3 and MMP-9 in the 
media of A549-TPα cells (Figure 21a). Different approaches were used to examine which 
of these MMPs can induce MCP-1 expression. As shown in Figure 21b, the CM from 
A549-TPα cells over-expressing MMP-9 did not induce the release of MCP-1 from these 
cells. Recombinant human MMP-3 did not stimulate the expression of MCP-1 either.  
However, MMP-1 significantly increased the expression of MCP-1 (Figure 21c).  
Further, the CM from MMP-1-siRNA-treated A549-TPα cells, in which the induction of 
MMP-1 by I-BOP was significantly decreased, had less effect on MCP-1 release than 
those media from control siRNA-treated cells (Figure 21d). These data indicate that 






Figure 21. MMP-1 mediates CM-I-BOP-induced MCP-1 from A549 cells 
(a) I-BOP induces MMP-1, MMP-3 and MMP-9 expression. The protein levels of MMP-
1, MMP-3 and MMP-9 in CM from A549-TPα cells treated with 0.1% ethanol (control) 
or I-BOP were determined by Western blot analysis. Data are representative of three 
independent experiments.  
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Figure 21. MMP-1 mediates CM-I-BOP-induced MCP-1 from A549 cells 
(b) The effects of MMP-9 on MCP-1 release. A549-TPα cells were transfected with 
pcDNA3 and pcDNA3-MMP-9 plasmids. After 48 h transfection, conditioned media 
were collected and MMP-9 protein levels were determined by Western blot (upper 
panel). A549 cells were treated for 16 h with above CM. MCP-1 protein levels were 
determined by Western blot (lower panel). Results are representative of three independent 
experiments.  (c) The effects of MMP-3 and MMP-1 on MCP-1 release. Control A549 
cells were treated with PBS (control), 5 nM MMP-1 or 5 nM MMP-3 for 16 h. The 
release of MCP-1 was determined by Western blot. Densitometric analysis of each band 














Figure 21. MMP-1 mediates CM-I-BOP-induced MCP-1 from A549 cells 
(d) The effects of MMP-1 knockdown in CM on MCP-1 release. A549-TPα cells were 
treated with either control or MMP-1 siRNA as indicated in Materials and methods. 
Conditioned media were collected and MMP-1 protein levels were determined by 
Western blot (upper panel). A549 cells were treated for 16 h with the above CM. MCP-1 
protein levels were determined by Western blot (lower panel). Densitometric analysis of 
each band was made and results were shown as fold change, ** P < 0.01 compared with 




4.3.3 MMP-1-induced MCP-1 release is PAR2 dependent  
        To determine if MMP-1-induced MCP-1 expression in A549 cells was achieved by 
cleaving and activating PARs, PARs specific antagonists were employed in this study.  
Unexpectedly, PAR1 antagonist SCH79797 at 50 nM did not block MMP-1-induced 
MCP-1 expression. However, SCH79797 at the same concentration effectively inhibited 
TFLLR-NH2, a PAR1-AP, -induced MCP-1 expression (Figure 22 and 24b). Similar 
results were obtained from the treatment with tc-Y-NH2, a PAR4 antagonist peptide 
(Figure 22 and 24b).  Interestingly, PAR2 antagonist ENMD-1068 completely inhibited 
MMP-1-induced MCP-1 expression (Figure 22). Comparing all PAR-APs, we found 
SLIGKV-NH2, a PAR2-AP, induced the most effective release of MCP-1 and PAR3-AP 
showed no induction of MCP-1 from A549 cells (Figure 23). The concentration of each 
PAR-AP used here is all optimal for the maximum induction. Trypsin, a known PAR2 
activating protease, also induced the expression of MCP-1 at 0.1µg/mL. Both inductions 
can be blocked totally by PAR2 antagonist (Figure 24a).   
        We also compared the increase of MCP-1 mRNA level by MMP-1 and PAR2-AP. 
Our RT-PCR results showed that a PAR2-AP induced more rapid expression of MCP-1 
than did MMP-1. PAR2-AP already stimulated the expression of MCP-1 mRNA at 1 h, 
and the expression reached the peak at 2 h. Nonetheless, MMP-1-treated cells displayed a 
delayed increase in the expression of MCP-1 mRNA (Figure 25).   In addition, CM-I-
BOP-induced MCP-1 release was also blocked by antagonist of PAR2 but not those of 
other PARs, which is in consistent with the results obtained from MMP-1 treatment 
(Figure 26).  
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        To further demonstrate that MMP-1-induced MCP-1 expression is mediated by 
PAR2, the siRNA of PAR2 was used to knock down its expression in A549 cells. As 
shown in Figure 27a, PAR2 siRNA at 100 nM successfully knocked down greater than 
80% of PAR2 protein expression in A549 cells. The inductions of MCP-1 by MMP-1 and 
by CM-I-BOP in PAR2 knockdown cells were decreased by ~45% and ~40%, 
respectively (Figure 27b and 27c). These data indicate that MMP-1-induced release of 

























Figure 22. PAR2 antagonist blocks MMP-1-induced MCP-1 release from A549 cells 
 Cells were treated with different PARs antagonists at optimized inhibitory 
concentrations for 30 min before stimulation with 5 nM MMP-1 for 16 h. PARs 
antagonists: PAR1, 50 nM SCH79797; PAR2, 150 µM ENMD-1068; PAR4, 300 µM tc-
Y-NH2.  MCP-1 protein levels were determined by Western blot. Densitometric analysis 
of each band was made and results were shown as fold change, ** P < 0.01 compared 















Figure 23. PAR-APs induce MCP-1 release from A549 cells 
Cells were treated with different PAR-APs: PAR1, 300 µM TFLLR-NH2; PAR2, 300 µM 
SLIGRL-NH2; PAR3, 300 µM TFRGAP-NH2; PAR4, 300 µM GYPGQV-NH2, for 16 h. 
MCP-1 protein levels were determined by Western blot. Densitometric analysis of each 
















Figure 24. PARs antagonists block PARs agonists-induced MCP-1 release from 
A549 cells 
(a) Cells were treated with or without 150 µM PAR2 antagonist, ENMD-1068, for 30 
min before incubation with PAR2 agonist, 0.1µg/ml trypsin (optimized concentration for 
PAR2 activation) and 300 µM SLIGRL-NH2, for 16 h. MCP-1 protein levels were 
measured by Western blot. Densitometric analysis of each band was made and results 
were shown as fold change, ** P < 0.01 compared with trypsin or SLIGRL-NH2 alone.  
(b) Cells were treated with or without PAR1 or PAR4 antagonist (50 nM SCH79797 for 
PAR1, 300 µM tc-Y-NH2 for PAR4) for 30 min before stimulation with PAR1-AP, 300 
µM TFLLR-NH2 or PAR4-AP, 300 µM GYPGQV-NH2, for 16 h. MCP-1 protein levels 
were determined by Western blot. Densitometric analysis of each band was made and 
results were shown as fold change, ** P < 0.01 compared with TFLLR-NH2 or 


















Figure 25. MMP-1 and PAR2-AP induce the transcription of MCP-1 
Cells were treated with 300 µM PAR2-AP, SLIGRL-NH2 or 5 nM MMP-1 at indicated 
time.   RT-PCR was carried out to identify mRNA levels of MCP-1 in cells.  Data are 























Figure 26. PAR2 antagonist blocks CM-I-BOP-induced MCP-1 release from A549 
cells 
Cells were treated with different PARs antagonists as described in Figure 23 for 30 min 
before stimulation with CM-I-BOP for 16 h. MCP-1 protein levels were determined by 
Western blot.  Densitometric analysis of each band was made and results were shown as 
























Figure 27. PAR2 siRNA suppresses MMP-1 and CM-I-BOP-induced MCP-1 release 
from A549 cells 
(a) Cells were treated with control or PAR2-siRNA as described in Materials and 
methods.   After treatment for 72 h, PAR2 protein levels were determined by Western 
blot analysis. (b) and (c) Control or PAR2-siRNA-treated cells were incubated with 5 nM 
MMP-1 or CM for 16 h. MCP-1 release were determined by Western blot. Densitometric 
analysis of each band was made and results were shown as fold change, ** P < 0.01 
compared with siControl. 
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4.4 Activation of TP increases MCP-1 expression and recruits macrophages to 
promote invasion of lung cancer cells  
            In addition to stimulating MCP-1 expression through released MMP-1, activation 
of TP can directly induce a rapid and significant expression of MCP-1 in A549-TPα cells.    
4.4.1 Induction of MCP-1 expression by activation of TP 
        To examine the effects of activation of TPα on the expression of MCP-1, A549-TPα 
cells were treated with TP agonist I-BOP at different time points. RT-PCR results showed 
that I-BOP induced a rapid and sustained expression of MCP-1 mRNA (Figure 28a).  
Quantitative real-time PCR assay was utilized to further determine the kinetics of MCP-1 
induction.  As shown in Figure 28b, the MCP-1 mRNA levels peaked at 4 h and still 
maintained a significant increase at 16 h after I-BOP treatment.  The protein levels of I-
BOP-induced MCP-1 expression were analyzed by Western blot assay.  The 
accumulation of MCP-1 in conditioned medium reached the maximum level at 24 h 
following stimulation (Figure 28c). Further, the induction of MCP-1 by I-BOP was dose-
dependent and the effect was significant even at 1 nM of I-BOP (Figure 28d).  In 
addition, the induction of MCP-1 by I-BOP was also observed in H157 and H460 human 
lung cancer cells that express high endogenous levels of TP [10] (Figure 29). When 
compared with other prostanoids including PGD2, PGE2, and PGF2α, I-BOP induced the 
most significant expression of MCP-1 in A549-TPα and H460 cells (Figure 30). 
Moreover, other prostanoids induced the peak expression of MCP-1 at a higher 
concentration (1µM). These data show that TP plays an important role in the production 





















Figure 28. Effects of I-BOP on MCP-1 expression in A549-TPα cells 
(a) I-BOP induced transcription of MCP-1. Cells were serum-starved for 24 h before 
treated with 50 nM I-BOP for the indicated time periods.  RNAs were isolated and RT-
PCR was carried out as described in Materials and methods. (b) MCP-1 mRNA induction 


















Figure 28. Effects of I-BOP on MCP-1 expression in A549-TPα cells 
(c) Time-dependent effects of I-BOP on MCP-1 protein expression.  After 24 h serum-
starvation, cells were treated with 50 nM I-BOP for the indicated time periods. Media 
were collected and proteins in each medium were concentrated by trichloroacetic acid 
(TCA) precipitation as described in Materials and methods. Concentrated samples were 
dissolved in SDS-PAGE sample loading buffer and analyzed by Western blot. (d) Dose-
dependent effects of I-BOP on MCP-1 protein expression.  After 24 h serum-starvation, 
cells were treated with indicated dose of I-BOP for further 24 h. Media were collected 


















Figure 29. I-BOP-induced MCP-1 protein expression in H157 and H460 cells 
After 24 h serum-starvation, cells were treated with indicated dose of I-BOP for further 
24 h. Media were collected and assayed as described in Figure 28c.  Data are 


















Figure 30. Comparison of I-BOP with other prostanoids on the induction of MCP-1 
in A549-TPα and H460 cells 
After 24 h serum-starvation, cells were treated with 50 nM I-BOP, 1µM PGD2, 1µM 
PGE2 or 1µM PGF2α for 24 h. Media were collected and assayed as described in Figure 
28c. Densitometric analysis of each band was made, and control untreated time point is 







4.4.2 SP1 is important for TPα-mediated MCP-1 expression 
        Upon ligand binding TP activates several downstream signal transduction cascades 
including PKC, ERK and NF-κB pathways that are involved in MCP-1 induction by 
several cytokines [118, 119, 175].  To investigate whether these pathways are responsible 
for I-BOP-induced MCP-1 expression, several specific inhibitors were used.  As shown 
in Figure 31, except TP antagonist, SQ29548, none of other inhibitors (GF109203X for 
PKC, U0126 for MEK/ERK, and MG132 for NF-κB pathways) has an effect on I-BOP-
induced MCP-1 expression indicating these pathways are not involved in the induction.  
In the proximal region of MCP-1 promoter, there is a GC rich element, which can bind 
nuclear factor SP1 to activate transcription (Figure 8) [115].  To elucidate whether SP1 is 
critical for MCP-1 induction by I-BOP, we employed mithramycin A (MTM), a specific 
SP1inhibitor preventing SP1 from binding to its consensus GC rich sites [176], and 
geldanamycin (GA), an inhibitor of Hsp90 which was also reported to affect binding of 
SP1 to gene promoter [177].  Both inhibitors significantly suppressed the induction of 
MCP-1 by I-BOP at protein and mRNA levels (Figure 32 and 33).  We further 
investigated the effects of I-BOP on SP1 translocation and expression.  As shown in 
Figure 34, SP1 protein started to accumulate in nucleus after incubation with I-BOP for 
30 min, and remained elevated at 4 h. I-BOP also induced the expression of SP1 at 2 h.  
Moreover, promoter-luciferase reporter bearing a fragment of 500 bp of human MCP-1 
gene promoter was used to evaluate the contribution of SP1 to I-BOP-induced MCP-1 
transcription.  SP1-binding element is located at -115 bp of MCP-1 promoter.  Site-
directed mutagenesis of SP-1 site resulted in a significant decrease of I-BOP-induced 
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promoter activity compared with the wild type (Figure 35). These data reveal that TP-











Figure 31. Effects of TP antagonist and several protein kinases inhibitors on I-BOP-
induced MCP-1 expression  
            Cells were treated with TP antagonist SQ29548 (10 µM), PKC inhibitor GF109203X 
(0.5 µM), MEK inhibitor U0126 (10 µM), and NF-κB activation inhibitor MG132 (10 
µM) for 30 min before incubation with 50 nM I-BOP for 24 h.  Media were collected 























Figure 32. Effects of SP1 inhibition on I-BOP-induced MCP-1 expression at protein 
levels 
Cells were treated with indicated concentrations of SP1 inhibitor mithramycin A (MTM) 
and Hsp90 inhibitor geldanamycin (GA) for 30 min before incubation with 50 nM I-BOP 























Figure 33. Effects of SP1 inhibition on I-BOP-induced MCP-1 expression at mRNA 
levels  
Cells were treated  with above inhibitors for 30 min before incubation with 50 nM I-BOP 
for 4 h. RNAs were isolated and real-time PCR was performed as described in Materials 






















Figure 34. SP1 protein levels are increased in the nuclei of A549-TPα cells following 
I-BOP stimulation  
Cells were treated with 50 nM I-BOP for the indicated time periods. Nuclear extract and   
whole cell lysate were prepared as described in Materials and methods. Protein level of 
SP1 was determined by Western blot.  Densitometric analysis of each band was made and 






















Figure 35. Regulation of MCP-1 promoter activity by SP1 
A549-TPα cells were transfected with luciferase reporter plasmids containing 500 bp of 
MCP-1 promoter sequence with either wild type or mutated SP1 binding sites. After 24 h 
transfection, cells were treated with vehicle control (0.1% ethanol) or 50 nM I-BOP for 
additional 18 h in serum free medium.  Luciferase assay was carried out as described in 






4.4.3 TP agonist-induced MCP-1 exhibits chemotactic effects on macrophages  
        To determine the chemotactic property of I-BOP-induced MCP-1 on macrophages, 
we examined the effect of conditioned medium from A549-TPα cells treated with or 
without I-BOP on the migration of murine macrophage RAW 264.7 cells.  As shown in 
Figure 36, conditioned media from I-BOP-treated cells significantly induced RAW 264.7 
cells migration compared to the media from vehicle (0.1% ethanol)-treated cells.  MCP-1 
neutralizing antibody and RS-102895, antagonist of CCR2, significantly decreased the 
chemotactic potency of medium from I-BOP-treated A549-TPα cells.  These data 
indicate that MCP-1 is a key chemotactic factor in A549-TPα cell culture which caused 































Figure 36. Effects of A549-TPα conditioned medium on the migration of RAW 264.7 
macrophages  
Chemotaxis assay of RAW 264.7 cells was carried out as described in Materials and 
methods. Preparation of conditioned medium (CM) from A549-TPα cells was also carried 
out as described in Material and methods section. CM-C is derived from vehicle-treated 
cells, and CM-I is derived from I-BOP-treated cells. SFM represents serum free medium. 
Rat IgG antibody which has no known specificity served as isotype control.  The 
concentrations of both antibodies were 5µg/mL original CM.  The concentration of RS-
102895 was 10 µM.  ** P < 0.01.  
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4.4.4 Co-culture of RAW 264.7 macrophages induces expression of metastatic genes 
by A549 cells   
        To elucidate the effects of macrophages on the invasiveness of A549 cells, we first 
used a trans-well co-culture system as shown in Figure 37.  In this co-culture system, 
there is no cell-cell direct contact and cells communicate with each other through soluble 
proteins.  Both control A549 and A549-TPα cells became more elongated and scattered 
after 12 h of co-culture with RAW264.7 cells than the cells grown alone (Figure 38). 
Furthermore, results from RT-PCR analysis showed that expressions of metastatic genes 
including several MMPs and VEGF were significantly elevated in either control A549 or 
A549-TPα cells co-cultured with macrophages (Figure 39).  Macrophages also induced 
MCP-1 expression by control A549 or A549-TPα cells (Figure 39).  As mentioned in 
3.1.2, Reduction of E-cadherin is tightly linked with cell migration and invasion [169]. 
Therefore, we examined whether macrophage-lung cancer cell interactions regulate E-
cadherin expression in control A549 or A549-TPα cells.  Indeed, co-culture with RAW 
264.7 macrophages significantly reduced the levels of E-cadherin in either type of A549 
cells (Figure 40).  Collectively, these data indicate that co-culture with macrophages may 





















Figure 37. Diagram of a transwell co-culture system  
RAW 264.7 cells and A549 cells were separately cultured for 24 h and then co-cultured 



























Figure 38. Transwell co-culture of RAW 264.7 macrophages induces morphological 
changes of A549 cells         
Either control A549 or A549-TPα cells became more scattered and spindle shaped after 
culture with RAW 264.7 cells. A549 cells were pictured after 12 h of culture with or 






















Figure 39. Co-culture of macrophages induces metastatic gene expression by A549 
cells  
The expressions of several metastatic genes in A549 and A549-TPα cells including 
MMPs, VEGF and MCP-1 mRNA after co-culture with macrophages were examined by 




















Figure 40. Co-culture of macrophages decreases E-cadherin expression by A549 
cells 
 A549 cells were collected after 24 h of culture with or without RAW 264.7 cells as 
described in Figure 37.  Protein level of E-cadherin was determined by Western blot as 









4.4.5 Co-culture of RAW 264.7 macrophages induces morphological changes and 
invasion of A549 cells 
        To further examine if macrophages promote invasion of A549 cells, we next used 
another co-culture system as shown in Figure 41.  In this system, cells communicate with 
each other via direct contact, which is closer to the physiological situation.  As shown in 
Figure 42, after 12 h of co-culture with macrophages, control A549 cells exhibit 
elongated protrusions indicating the invasive potential. This morphology still sustained 
after 36 h of co-culture.  In addition, in matrigel invasion assay, co-culture with 
macrophages induced a 2.5-fold increase in cellular invasiveness of control A549 cells 
through matrigel relative to those cells grown alone (Figure 43).  These results indicate 

















      Figure 41. Diagram of a direct co-culture system 












Figure 42. Direct co-culture of macrophages induces morphological changes of A549 
cells  
A549 cells exhibit elongated shape after culture with RAW 264.7 macrophages. A549 
cells were plated into a 12-well plate with or without RAW 264.7 cells as described in 
Figure 41. Cells were pictured at the indicated time points. In the lower panel, those small 














Figure 43. Co-culture of macrophages induces invasion of A549 cells 
 Invasion assay of A549 cells was carried out as described in Material and methods. ** P 














5.1 Increased expression of MMPs mediates TP agonist-induced invasion in A549-
TPα cells  
        There is much evidence that COX-2 and one of its derived products, prostaglandin 
E2 (PGE2) mediate invasion and metastasis of various cancers through upregulation of 
MMPs [63-65, 178]. TXA2, another product downstream of COX-2, is also reported to be 
involved in cancer invasion and metastasis [46, 179].  However, there are few data on the 
connection between TXA2-TP and MMPs in promotion of cancer invasion and 
metastasis.    In this study, it was demonstrated that one TXA2 mimetic, I-BOP, induced 
significantly the expression of several MMPs, such as MMP-1, MMP-3, MMP-9 and 
MMP-10 in both A549-TPα and A549-TPβ cells.  This study is the first to establish the 
association between TP and MMPs in cancer; it also provides the evidence that TP 
mediates cellular invasive potential by inducing MMPs.  
        To study the mechanisms of I-BOP-induced MMPs expression, MMP-1 was chosen 
as a model system to explore the roles of nuclear factors and signal transduction pathways 
in TP-mediated MMPs gene expression. Using specific pharmacological inhibitors of 
various signaling molecules which were reported to be activated in TP-mediated 
signaling transductions [10, 26, 180], we identified PKC and MAPK/ERK but not 
SAPK/JNK, P38 MAPK or PI3K pathways are involved in I-BOP-stimulated MMP-1 
expression.  Recently, Uchiyama et al. reported that both MMPs and PKC inhibitors 
inhibited TP agonist U46619-induced shedding of heparin-binding epidermal growth 
factor (HB-EGF)[181], suggesting the involvement of PKC in TP-mediated MMPs 
expression or activation.  
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        We further explored downstream targets of PKC and ERK pathways in the 
regulation of MMP-1 expression. As we mentioned in 1.5.1, based on the compositions 
of cis-acting elements in their promoters, MMPs have been roughly grouped into three 
categories. Group 1 consists of the majority of the MMPs: MMP-1, 3, 7, 9, 10, 12, 13 and 
19 which contain a TATA box and an AP-1 site in the proximal region of their 
promoters.  In the present study, MMPs induced by I-BOP belong to Group 1, suggesting 
that transcription factor AP-1 can be activated and involved in TP-mediated signaling.  It 
has been previously reported that ERK-AP1 pathway play an important role in cytokine 
and growth factor stimulation of expression of MMPs.  Constitutive activation of ERK 
transactivates the MMP-1 promoter through phosphorylation and activation of AP-1 and 
Ets proteins [182].  EGF activation of the ERK pathway can activate multiple MMP 
genes simultaneously, including MMP-1[75], MMP-3[78], MMP-7, MMP-9[80] and 
MMP-14 [183].  PKC has also been shown to regulate MMPs expression through 
activation of AP-1[184].  Activation of AP-1 by TP agonist has been found in human 
vascular smooth muscle cells and endothelial cells [185, 186].  In this study, we found 
that I-BOP induced significantly the phosphorylaton of c-Jun and the expression of c-Fos, 
the major subunits of AP-1 transcription factors.  Inhibition of PKC and ERK repressed 
the induction of p-c-Jun and c-Fos, suggesting that PKC and ERK pathways regulate 
MMP-1 expression through targeting at AP-1 factors.  Both ERK and JNK can directly 
activate c-Jun according to others report [187].  We also detected the activation of JNK in 
I-BOP-treated cells and inhibition of JNK partially blocked I-BOP-induced p-c-Jun.  
However, JNK inhibitor neither decreased the induction of MMP-1 nor changed the 
expression of c-Fos, suggesting that activation of c-Jun alone is not sufficient to induce 
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TP-mediated MMP-1 expression.  Activation of both c-Jun and c-Fos is required for TP-
mediated MMP-1 regulation.  This is consistent with the findings of Hu et al. [188]who 
demonstrated that EGF and platelet-derived growth factor (PDGF) could not induce the 
expression of MMP-1 and MMP-3 even though these growth factors induced 
significantly the expression of c-Jun, JunB and other AP-1 proteins in c-fos-deficient cell 
lines.  To further define the role of AP-1 in I-BOP-induced MMP-1 transcription, we 
mutated three AP-1 sites separately in the region close to the transcription start site of 
MMP-1 promoter. The results showed that the proximal AP-1 site, -73 bp relative to the 
transcription start site, is critical to I-BOP-induced MMP-1 transcription.   
        In addition to AP-1, our results indicated that transcription factor C/EBPβ was also 
involved in I-BOP-induced MMP-1 expression.  Previously, it was demonstrated that IL-
1β and IL-17 induced MMP-1 expression through ERK-dependent induction and 
phosphorylation of C/EBPβ on Thr-235[171, 172, 189].  We showed that inhibition of 
ERK blocked I-BOP-induced expression and phosphorylation of C/EBPβ and knockdown 
of C/EBPβ by siRNA decreased I-BOP-induced MMP-1 expression. These results 
support the contention that C/EBPβ plays an important role in inducing MMP-1 
expression.  It has been shown that there are several silencer elements in the region 
between -1,653 and -2,672 bp of MMP-1 promoter which suppress the transcription of 
MMP-1[190]. The C/EBPβ site located at -2,921 bp is outside of the region of repression. 
Therefore, deletion mutation of this C/EBPβ site significantly decreased the basal and I-
BOP-induced MMP-1transcription.  In addition to MMP-1, MMP-3 and MMP-10 also 
contain multiple putative C/EBP sites in their promoters.  Silencing C/EBPβ decreased 
IL-1β-induced MMP-3 and MMP-10 gene expression [172].  Our previous study 
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indicated that C/EBP plays an important role in I-BOP-stimulated COX-2 transcription 
[166].  Taken together, these data suggest that the role of C/EBP signaling pathways in 
TP-mediated transcriptional regulation of cancer related genes cannot be overlooked.   
        Our data show that I-BOP increased invasiveness of A549-TPα and A549-TPβ cells 
maximally at low concentration (10 nM) although a higher concentration was needed to 
induce maximal expression of MMPs (Figure 13). This could be due to the fact that a 
higher concentration of TP agonist reduced tumor cell migration [20]. It seems that TP-
mediated cell migration is in a temporal and spatial manner [20].  Further studies are 
required to provide a plausible explanation for the poor correlation.   
         In our studies, MMP-1 and MMP-9 function as mediators of I-BOP-induced cell 
invasion which are supported by other reports that short hairpin RNA of MMP-1 reduced 
invasiveness of breast cancer cells in vitro and prevent lung metastasis of melanomas 
[191, 192],  and inhibition of MMP-9 blocked chronic lymphocytic leukemia B-cell 
invasion through matrigel [193].  These results may be due to the degradation of ECM by 
MMPs. Nevertheless, MMP-1 was recently found to activate protease activated receptor-
1(PAR-1) to promote invasion of breast cancer and melanoma cells [69, 70]. MMP-9 has 
also been found to display anti-apoptotic effects on tumor cells that are independent of its 
catalytic activity [194]. These newly discovered functions of MMP-1 and MMP-9 may 
also be involved in TP-mediated cell invasion.    
         Moreover, COX-2 and MMP-1 were found to be part of the clinically validated 
lung metastasis gene signature (LMS) genes. Knockdown of COX-2 and MMP-1/2 genes 
synergistically inhibited metastasis of breast cancer [195].  We previously demonstrated 
that I-BOP significantly increased COX-2 expression in A549-TPα cells. The induced 
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COX-2 produced more prostaglandins and TXA2 as a result of positive feedback [166]. 
Taken together, these studies suggest that targeting TP may prevent metastasis of cancer 
effectively via suppression of both COX-2 and MMP-1 production.      
         GM6001, a general inhibitor of MMPs, inhibited both basal and I-BOP-induced 
invasion.  These results suggest that MMPs, other than MMP-1 and MMP-9, such as 
MMP-3 and MMP-10 which are also induced by I-BOP are involved in TP-mediated cell 
invasion. Elevated levels of these MMPs were previously reported to be critical for 
cancer invasion and metastasis [196-198].  
        In summary, our findings indicate that TXA2-TP mediates cancer cell invasion 
through upregulation of several MMPs. PKC-, ERK-AP-1 and ERK-C/EBPβ pathways 
are involved in TP-mediated MMP-1 expression. Figure 44 depicts signaling pathways 












5.2 MMP-1-mediated release of MCP-1 by conditioned media from TP agonist-
treated A549-TPα cells is through activation of PAR2 
         MMP-1 was reported to promote melanoma progression through both its 
collagenase activity and its PAR1 activating function [70]. MMP-1/PAR1 signaling 
induces a variety of genes which can contribute to melanoma invasion and metastasis.  
Here, it was demonstrated that the increased MMP-1 could induce the expression of 
MCP-1, a potential biomarker for tumor invasion and metastasis, by autocrinely acting on 
cancer cells surface receptor PAR2 in A549 cells.   
        Except for MMP-1, activation of TPα also induces MMP-3 and MMP-9 expression. 
MMP-3 and MMP-1 have been reported to induce macrophage MMP-9 expression in 
TNF-α and COX-2 dependent manner [199].  However, in our system neither MMP-3 nor 
MMP-9 can stimulate the release of MCP-1 from A549 cells, indicating the specific 
function of MMP-1 in MCP-1 gene induction.   MMP-1 also induces an array of genes 
expression via PAR1 in endothelial cells in addition to melanoma cells [200].  However, 
MMP-1 and thrombin, a known PAR1 ligand, induce expression of different subsets of 
pro-angiogenic genes.  PAR1 antagonist, SCH79797 cannot inhibit MMP-1-induced 
VEGFC, NOTCH4, AKT1 and ANGPT2 genes expression in endothelial cells [200].  
Moreover, MMP-1-induced FGFR2, IGF1, SERPINB5 and S100A4 genes expression 
have not been associated with thrombin/PAR1 signaling in melanoma cells [70]. These 
studies indicate that MMP-1 may target other receptors than PAR1 to induce these genes 
expression.  Our data showed that antagonist of PAR2, but not that of PAR1 or PAR4, 
inhibits MMP-1-induced MCP-1 release from A549 cells indicating the involvement of 
PAR2 in this process.  The concentration of SCH79797 we used was 50 nM, which was 
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sufficient to block PAR1-AP-induced MCP-1 release. The same concentration also 
effectively blocked MMP-1-induced gene expressions in melanoma cells [70].  This is 
also supported by studies on MCP-1 induction using different PAR-APs.  Although 
PAR1-AP and PAR4-AP can increase the expression of MCP-1, PAR2-AP induced more 
significantly MCP-1 release compared with them (p<0.001).  Furthermore, Asokananthan 
et al. [201] reported that agonist peptides of PAR1, PAR2 and PAR4 but not that of 
PAR3 stimulated the release of other cytokines IL-6 and IL-8 from A549 cells with a 
rank order of potency of PAR2>PAR4>PAR1, which is in the same order as that for 
MCP-1 induction in our studies.   
        PAR2 has been shown to play an important role in cancer progression.  PAR2 
mediates tumor or stromal cells-derived proteases to shape tumor microenvironment by 
inducing various growth factors, pro-angiogenic and immune modulating cytokines 
[202].  It has been found that PAR2 signaling in breast cancer cells induced an array of 
pro-angiogenic factors and immune regulators, such as VEGF [102], Cyr61, VEGFC, 
CTGF, CXCL1, IL8, CSF1 and CSF2 [103]. Although activation of PAR1 also up-
regulated some of those factors in breast cancer cells, PAR2 was the major mediator for 
the induction of immune regulators CXCL1, IL8 and CSF2.  MCP-1, another immune 
regulating cytokine, is often up-regulated together with IL-8 by extracellular stimuli [203, 
204]. Thus, PARs-mediated MCP-1 expression may also mainly depend on PAR2 
activation.  
        PAR-APs activate PARs by directly binding with their respective receptors without 
the cleavage process. Accordingly, the induction of MCP-1 mRNA by SLIGKV-NH2, a 
PAR2-AP, was rapid.  However, MMP-1 induced a delayed MCP-1 transcription 
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suggesting that MMP-1 may behave like other proteases by proteolytic unmasking of the 
tethered ligand first before the activation of PAR2.   How MMP-1 cleaves and activates 
the N-terminus of PAR2 needs to be determined further.  
        Induction of MCP-1 by thrombin/PAR1 signaling has been observed in different cell 
types [106, 205, 206].  Similarly, induction of pro-angiogenic gene expressions by 
thrombin and MMP-1 was found also via PAR1 in human microvessel endothelial cells 
[200].  However, it appears that thrombin and MMP-1 cleave and activate PAR1 in a 
different manner.  Thrombin cleaves PAR1 at R41-S42 and exposes SFLLRN sequence 
to activate PAR1, whereas MMP-1 cleaves PAR1 at two different locations (F87-I88 and 
L44-L45).  Cleavage at L44-L45 results in decreasing or abolishing the functional 
activity of SFLLRN sequence [207].   Consequently, MMP-1 may also cleave and 
activate other PARs than PAR1.  PAR2 appears to be an ideal target of MMP1 since 
antagonist of PAR2, ENMD-1068, but not that of PAR1 or PAR4 was able to block 
MMP-1 induced MCP-1 expression. 
        In conclusion, our studies, for the first time, provide the evidence that MMP-1-
induced MCP-1 expression is dependent on PAR2 activation in A549 cells.  Although the 
mechanism of how MMP-1 activates PAR2 remains unknown, we linked TXA2/TP 
signaling with PARs signaling in lung cancer cells by TP-mediated MMP-1 release. 
5.3 Activation of TP increases MCP-1 expression and recruits macrophages to 
promote invasion of lung cancer cells  
        In addition to MMP-1, released by TP activation, can induce MCP-1 expression in 
A549 cells, TP agonist can directly stimulate the production of MCP-1 in A549-TPα 
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cells.  In this study, we also suggest that MCP-1 may attract macrophages to cancer cells, 
thereby promoting their invasion.  
        TXA2 has been shown to induce MCP-1 expression in vascular endothelial cells and 
also other cytokines in WISH cells (an amnion epithelium-derived cell line) [208, 209].  
In addition, a recent report showed that TXAS inhibitor ozagrel suppressed MCP-1 and 
IL-8 gene expression and inflammatory cell accumulation in a lung injury model 
indicating the role of TXA2 in regulation of these processes [210]. Cancers are considered 
as chronic wounds never heal. Therefore, they share certain characteristics.  Several CC 
chemokines including MCP-1 were found to be highly expressed in human NSCLC 
tumor tissues and the levels of MCP-1 also significantly correlated to macrophage 
infiltration [138].  These findings led to the hypothesis that TXA2 might be involved in 
lung cancer development via MCP-1-mediated macrophage recruitment.  Especially 
compared to other prostanoids, TXA2 agonist induced the most expression of MCP-1 in 
both H460 and A549-TPα cells indicating a significant contribution of TXA2-TP axis to 
MCP-1 production.   
        Mechanisms of regulation of MCP-1 by I-BOP were further studied. There are 
several cis-acting transcriptional regulatory elements including NF-κB, AP1 and SP1 
sites in the promoter region of human MCP-1 gene (Figure 8).  Expression of MCP-1 
induced by IL-1β was regulated by PKC-dependent NF-κB activation in smooth muscle 
cells [118]. U46619, another TP agonist, was also reported to induce MCP-1 expression 
via PKC-dependent induction of NF-κB and AP-1 binding activity in vascular endothelial 
cells [208]. Activation of PKC, NF-κB and AP-1 by TP-mediated G protein signaling has 
been found in several other cell types including A549 cells [166].  However, in this study, 
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neither PKC inhibitor GF109203X nor NF-κB activation inhibitor MG132 had any effect 
on I-BOP-induced expression of MCP-1. As presented in 4.2, I-BOP-induced MMP-1 
expression was mediated by PKC and ERK-dependent AP-1 activation in the same cell 
lines. Nevertheless, inhibition of ERK did not block I-BOP-induced MCP-1 expression 
either, suggesting AP-1 was not involved in MCP-1 regulation by I-BOP in A549-TPα 
cells.  These data indicated that separate signaling pathways were involved in the 
expression of downstream targets induced by I-BOP activation of TP.  It is also possible 
that MCP-1 regulation is tissue-specific, and NF-κB and AP-1 are not important for 
MCP-1 expression in lung epithelial cancer cells.  A separate study in fibroblast 3T3 cells 
showing that the expression of MMP-1 induced by growth factors was c-Fos-dependent, 
whereas that of MCP-1 was not provides support to our proposition.   Moreover, it has 
been reported that PDGF induction of MCP-1 transcription requires SP1 but not NF-κB 
and AP-1 response elements in its promoter region in fibroblast [115].  Therefore, we 
propose that in cancer cells I-BOP may regulate MCP-1 expression in a way similar to 
how PDGF does in fibroblast.  We observed that SP1 was increased in nuclei after I-BOP 
stimulation and SP1 inhibitor blocked I-BOP-induced MCP-1 expression.  Furthermore, 
using GC-rich promoter region of 12(S)-lipoxygenase as a probe, Chang and his 
colleagues identified that Hsp90 interacts with SP1 and modulates its promoter binding 
ability [177].  In the present study, indirect inhibition of SP1 by Hsp90 inhibitor 
geldanamycin blocked I-BOP-induced MCP-1 expression at protein as well as mRNA 
levels.  Moreover, the results obtained from MCP-1 promoter-luciferase reporter assay 
further indicate the critical role of SP1 binding site in MCP-1 regulation by I-BOP. 
Although the upstream signals by which TP regulates SP1 expression and translocation 
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need further studies, the results presented here demonstrated that I-BOP induced MCP-1 
expression in A549-TPα cells by SP1-dependent but NF-κB and AP-1-independent 
mechanism.  
        As mentioned in 1.8.1, macrophages have been classified into M1 and M2 two 
major groups. M1 macrophages inhibit tumor progression, whereas M2 macrophages 
promote tumor progression. Both M1 and M2 macrophages could be present in tumor 
islet. Here, we employed RAW264.7 macrophages to study the interactions between lung 
cancer cells and macrophages. RAW 264.7, a murine macrophage cell line, can be 
polarized into either M1 or M2 macrophages [211]. Interactions of RAW 264.7 
macrophages with human cancer cells such as lymphoma and breast cancer cells have 
been reported in previous studies [212, 213]. Furthermore, human MCP-1 and mouse 
MCP-1 which is truncated at the C terminus are highly homologous. Indeed, human 
MCP-1 even has a higher chemotactic potency to murine monocytes than full length of 
murine MCP-1 due to the less glycosylation of human MCP-1 C terminus [214].  
Therefore, RAW 264.7 macrophages can serve as an appropriate cell line to study TP-
mediated interactions between lung cancer cells and macrophages.          
        Macrophages contribute to various aspects of cancer progression such as cancer cell 
proliferation, survival, invasion, metastasis and angiogenesis.  In this study, co-culture of 
macrophages with A549 cells stimulated gene expressions of several MMPs and VEGF 
by A549 cells.  It was reported that A549-TPα cells induced tumor formation and 
angiogenesis in nude mice through induction of VEGF expression [37].  In 3.2 we also 
showed that I-BOP-induced invasion of A549-TPα cells was mediated by increased 
expression of several MMPs such as MMP-1 and MMP-9.  Here, macrophages induced 
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these genes, and thus enhanced the effects of TP-mediated angiogenesis and invasion of 
cancer cells.  MCP-1 was also induced in A549 cells by co-culture with macrophages 
forming a positive feedback loop that might reinforce the recruitment of more 
macrophages to promote cancer cell invasion.        
        Tumors are very heterogeneous and contain numerous subpopulations of cells [215] 
that may express different levels of TP. We show here that once TXA2 initiates a 
signaling cascade leading to the release of MCP-1 from tumor cells expressing high 
levels of TP, the subsequent recruited macrophages could increase the invasion of tumor 
cells regardless of their TP levels.  Therefore, TP expands its influence on tumor 
progression through MCP-1-mediated macrophage recruitment.    
        In summary, TP-mediated interactions and relationships among MMP-1, PAR2 and 
MCP-1, as well as macrophages leading to an increased invasive potential of carcinoma 
























Figure 45. Illustration of a tentative mechanism for TP-mediated invasion of cancer 
cells 
Black arrows (      ) represent pathways mediated by direct activation of TP.  Gray arrow  
(     ) represents pathway mediated by PAR2 activation. Dashed arrows (     ) represent 
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6. Summary and conclusions 
        In this dissertation, I investigated the cellular and molecular mechanisms by which 
thromboxane A2 receptor-mediated cancer cell invasion.  The findings of this dissertation 
research are summarized below: 
(1)  Using human lung adenocarcinoma cells A549 overexpressing TPα or TPβ as a 
model system, we found that activation of either isoform of TP decreased the 
expression of cell-cell adhesion molecule E -cadherin, changed epithelial cell 
morphology to scattered spindle-shaped morphology, and induced invasion in 
these cells. 
(2) Further studies revealed that activation of TPs induced expression of several 
MMPs including MMP-1, MMP-3, MMP-9, and MMP-10.  MMPs general 
inhibitor and siRNA of MMP-1 and MMP-9 blocked TP agonist-induced invasion 
of A549-TPα cells indicating the positive correlation of MMPs to TP-mediated 
cancer cell invasion.  We also identified several key signal transduction pathways 
involved in MMP-1 gene regulation including ERK-AP1, PKC-AP1, and ERK-
C/EBPβ pathways.   
(3) PAR2 was identified as a novel target of MMP-1 which induced MCP-1 
expression in A549 cells.  Conditioned media from I-BOP-treated A549-TPα cells 
(CM-I-BOP) also induced MCP-1 expression via MMP-1.  PAR2 antagonist and 
siRNA blocked both MMP-1 and CM-I-BOP-induced MCP-1 expression.  
(4) Activation of TP could directly induce the release of MCP-1via SP1 dependent 
pathway.  MCP-1 recruited macrophages which in turn stimulated the expression 
of several metastatic genes including MMPs and VEGF, therefore, enhanced the 
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invasion of A549 cells.  Macrophages also induced a further generation of MCP-1 
by A549 providing a positive feedback loop to recruit more macrophages to 
enhance cancer cell invasion.  
(5) Finally, the rapid expression of MCP-1 induced by activation of TPα is followed 
by delayed expression of MCP-1 either induced by MMP-1or macrophages to 
ensure continued supply of chemotactic MCP-1 for recruitment of macrophages 
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